
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2006

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 001-31922

TEMPUR-PEDIC INTERNATIONAL INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

33-1022198
(I.R.S. Employer
Identification No.)

1713 Jaggie Fox Way
Lexington, Kentucky 40511
(Address, including zip code, of registrant's principal executive offices)

Registrant's telephone number, including area code: (800) 878-8889

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes No

The number of shares outstanding of the registrant's common stock as of July 31, 2006 was 82,869,227 shares.

TABLE OF CONTENTS

	<u>Page</u>
Special Note Regarding Forward-Looking Statements	3
PART I. FINANCIAL INFORMATION	
ITEM 1. Financial Statements	
Condensed Consolidated Statements of Income	4
Condensed Consolidated Balance Sheets	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	39
ITEM 4. Controls and Procedures	40
PART II. OTHER INFORMATION	
ITEM 1. Legal Proceedings	41
ITEM 1A. Risk Factors	41
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	50
ITEM 3. Defaults upon Senior Securities	50
ITEM 4. Submission of Matters to a Vote of Security Holders	50
ITEM 5. Other Information	51
ITEM 6. Exhibits	51
Signatures	52

Special Note Regarding Forward-Looking Statements

This quarterly report on Form 10-Q, including the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include information concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, the impact of the adoption of recently issued accounting pronouncements, the putative securities class action lawsuits and related lawsuits recently filed, the rollout and market acceptance of new products, our investments to increase our global brand awareness, the Company’s expectations regarding its gross margin over the second half of 2006, the Company’s expectations regarding additional opportunities for growth, plans to increase sales and reduce costs, the impact of increases in raw materials costs, the construction of our new manufacturing facility in New Mexico, and other information that is not historical information. Many of these statements appear, in particular, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in ITEM 2 of Part I of this report. When used in this report, the words “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations and various assumptions. There can be no assurance that we will realize our expectations or that our beliefs will prove correct.

There are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this report. Important factors that could cause our actual results to differ materially from those expressed as forward-looking statements are set forth in this report, including under the heading “Risk Factors” under ITEM 1A of Part II. There may be other factors that may cause our actual results to differ materially from the forward-looking statements.

All forward-looking statements attributable to us apply only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. Except as may be required by law, we undertake no obligation to publicly update or revise any of the forward-looking statements, whether as a result of new information, future events, or otherwise.

When used in this report, except as specifically noted otherwise, the term “Tempur-Pedic International” refers to Tempur-Pedic International Inc. only, and the terms “Company,” “we,” “our,” “ours” and “us” refer to Tempur-Pedic International Inc. and its consolidated subsidiaries.

[Table of Contents](#)

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Net sales	\$ 218,962	\$ 192,615	\$ 447,548	\$ 414,994
Cost of sales	112,446	94,080	229,778	202,216
Gross profit	106,516	98,535	217,770	212,778
Selling and marketing expenses	40,353	38,149	85,095	83,118
General and administrative expenses	17,950	15,276	36,405	34,366
Research and development expenses	951	513	1,791	1,317
Operating income	47,262	44,597	94,479	93,977
Other income (expense), net:				
Interest expense, net	(6,217)	(4,864)	(10,674)	(10,227)
Loss on extinguishment of debt	—	—	—	(717)
Other income (expense), net	(55)	412	(148)	327
Total other expense	(6,272)	(4,452)	(10,822)	(10,617)
Income before income taxes	40,990	40,145	83,657	83,360
Income tax provision	14,878	15,295	30,652	31,760
Net income	\$ 26,112	\$ 24,850	\$ 53,005	\$ 51,600
Earnings per share:				
Basic	\$ 0.31	\$ 0.25	\$ 0.61	\$ 0.52
Diluted	\$ 0.30	\$ 0.24	\$ 0.59	\$ 0.50
Weighted average shares outstanding:				
Basic	84,377	98,792	86,848	98,607
Diluted	87,460	103,431	90,246	103,315

See accompanying Notes to Condensed Consolidated Financial Statements.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)

	June 30, 2006	December 31, 2005
	(Unaudited)	
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 15,812	\$ 17,855
Accounts receivable, net	123,916	111,726
Inventories	71,773	81,064
Prepaid expenses and other current assets	11,336	11,072
Income taxes receivable	—	19
Deferred income taxes	7,819	6,532
	<hr/>	<hr/>
Total Current Assets	230,656	228,268
Property, plant and equipment, net	206,519	193,224
Goodwill	200,045	199,962
Other intangible assets, net	72,414	73,908
Deferred financing and other non-current assets, net	6,969	6,949
	<hr/>	<hr/>
Total Assets	\$ 716,603	\$ 702,311
	<hr/>	<hr/>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable	\$ 37,590	\$ 33,639
Accrued expenses and other	63,276	56,570
Income taxes payable	12,410	—
Current portion of long-term debt	22,673	30,770
	<hr/>	<hr/>
Total Current Liabilities	135,949	120,979
Long-term debt	394,461	313,711
Deferred income taxes	39,262	40,386
Other non-current liabilities	720	906
	<hr/>	<hr/>
Total Liabilities	570,392	475,982
Commitments and contingencies—see Note 8		
Stockholders' Equity:		
Common stock—\$.01 par value; 300,000 shares authorized; 99,215 shares issued as of June 30, 2006 and December 31, 2005	992	992
Additional paid in capital	259,803	255,369
Deferred stock compensation—net of amortization of \$12,312 as of December 31, 2005	—	(2,196)
Retained earnings	84,179	46,245
Accumulated other comprehensive income	2,293	1,137
Treasury stock, at cost; 16,362 and 6,767 shares as of June 30, 2006 and December 31, 2005, respectively	(201,056)	(75,218)
	<hr/>	<hr/>
Total Stockholders' Equity	146,211	226,329
	<hr/>	<hr/>
Total Liabilities and Stockholders' Equity	\$ 716,603	\$ 702,311
	<hr/>	<hr/>

See accompanying Notes to Condensed Consolidated Financial Statements.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	Six Months Ended June 30,	
	2006	2005
	(Unaudited)	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 53,005	\$ 51,600
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	12,373	12,590
Amortization of deferred financing costs	820	1,303
Loss on extinguishment of debt	—	717
Amortization of stock-based compensation	1,504	1,649
Allowance for doubtful accounts	1,491	1,310
Deferred income taxes	(2,411)	(1,561)
Foreign currency adjustments	274	194
Loss on sale of equipment and other	288	575
Changes in operating assets and liabilities:		
Accounts receivable	(9,516)	(9,114)
Inventories	10,871	(18,057)
Prepaid expenses and other current assets	72	1,133
Accounts payable	2,231	(1,597)
Accrued expenses and other	3,575	(4,983)
Income taxes	11,933	13,365
Net cash provided by operating activities	<u>86,510</u>	<u>49,124</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for trademarks and other intellectual property	(503)	(1,138)
Purchases of property, plant and equipment	(18,561)	(48,726)
Proceeds from sale of equipment	31	182
Net cash used by investing activities	<u>(19,033)</u>	<u>(49,682)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from long-term revolving credit facility	133,500	53,000
Repayments of long-term revolving credit facility	(13,000)	(17,000)
Repayments of long-term debt	(52,873)	(32,276)
Repayments of Series A Industrial Revenue Bonds	(1,920)	—
Common stock issued, including reissuances of treasury stock	2,851	1,697
Excess tax benefit from stock based compensation	5,140	—
Treasury stock repurchased	(144,000)	—
Payments for deferred financing costs	(702)	—
Net cash (used) / provided by financing activities	<u>(71,004)</u>	<u>5,421</u>
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH	<u>1,484</u>	<u>(5,063)</u>
Decrease in cash and cash equivalents	<u>(2,043)</u>	<u>(200)</u>
CASH AND CASH EQUIVALENTS, beginning of period	<u>17,855</u>	<u>28,368</u>
CASH AND CASH EQUIVALENTS, end of period	<u>\$ 15,812</u>	<u>\$ 28,168</u>
Supplemental cash flow information:		
Cash paid during the period for:		
Interest	\$ 12,736	\$ 9,542
Income taxes, net of refunds	\$ 17,122	\$ 20,080

See accompanying Notes to Condensed Consolidated Financial Statements.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except per share amounts)

(1) Summary of Significant Accounting Policies

(a) *Basis of Presentation and Description of Business*—Tempur-Pedic International Inc., a Delaware corporation, together with its subsidiaries is a U.S.-based, multinational company. As used herein, the term “Tempur-Pedic International” refers to Tempur-Pedic International Inc. only, and the term “Company” refers to Tempur-Pedic International Inc. and its subsidiaries.

The Company manufactures, markets, and sells viscoelastic products including pillows, mattresses, and other related products. The Company manufactures essentially all its pressure-relieving TEMPUR[®] products at two manufacturing facilities, with one located in Denmark and one in the U.S. The Company has sales distribution subsidiaries operating in the U.S., Europe, and Asia Pacific and has third party distribution arrangements in certain other countries where it does not have subsidiaries. The Company sells its products in over 70 countries. The Company sells its products through four sales channels: Retail, Direct, Healthcare, and Third Party, and extends credit based on the creditworthiness of its customer.

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles in the United States (U.S. GAAP) for complete financial statements. Accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements of the Company and related footnotes for the year ended December 31, 2005, included in the Company’s Annual Report on Form 10-K. The balance sheet as of December 31, 2005 has been derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

The results of operations for the interim periods are not necessarily indicative of results of operations for a full year. It is the opinion of management that all necessary adjustments for a fair presentation of the results of operations for the interim periods have been made and are of a recurring nature unless otherwise disclosed herein.

(b) *Reclassifications*—Certain prior period amounts have been reclassified to conform to the 2006 presentation. Income taxes are presented separately in operating activities in the Condensed Consolidated Statement of Cash Flows. Also, long-term and short-term revolving credit facility activities are combined in financing activities in the Condensed Consolidated Statement of Cash Flows.

(c) *Basis of Consolidation*—The accompanying financial statements include the accounts of Tempur-Pedic International and its subsidiaries. All subsidiaries are wholly owned. All material intercompany balances and transactions have been eliminated.

(d) *Use of Estimates*—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(e) *Foreign Currency Translation*—Assets and liabilities of non-U.S. subsidiaries, whose functional currency is the local currency, are translated at period-end exchange rates. Income and expense items are translated at the weighted average rates of exchange prevailing during the period. The adjustment resulting from translating the financial statements of foreign subsidiaries is included in Accumulated other comprehensive income, a component of Stockholders’ Equity. Foreign currency transaction gains and losses are reported in results of operations.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

(f) *Financial Instruments and Hedging*—Derivative financial instruments are used within the normal course of business principally to manage foreign currency exchange rate risk. These instruments are generally short term in nature and are subject to fluctuations in foreign exchange rates and credit risk. Credit risk is managed through the selection of sound financial institutions as counterparties. The changes in fair market value of foreign exchange derivatives are recognized currently through income. The changes in fair market value of derivative financial instruments used to manage interest rates are recognized through Accumulated other comprehensive income.

(g) *Cash and Cash Equivalents*—Cash and cash equivalents consist of all investments with initial maturities of three months or less.

(h) *Inventories*—Inventories are stated at the lower of cost or market, determined by the first-in, first-out method, and consisted of the following:

	June 30, 2006	December 31, 2005
Finished goods	\$51,633	\$ 61,071
Work-in-process	6,941	7,427
Raw materials and supplies	13,199	12,566
	<u>\$71,773</u>	<u>\$ 81,064</u>

(i) *Long Lived Assets*—In accordance with Statement of Financial Accounting Standards (SFAS) 144, “Accounting for the Impairment or Disposal of Long-lived Assets,” long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the asset to the estimated future net cash flows expected to be generated by the asset. If estimated future undiscounted net cash flows are less than the carrying amount of the asset or group of assets, the asset is considered impaired and an expense is recorded in an amount required to reduce the carrying amount of the asset to its then fair value.

(j) *Goodwill and Other Intangible Assets*—The Company follows SFAS 142, “Goodwill and Other Intangible Assets.” SFAS 142 requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment in accordance with SFAS 144. The Company performs an annual impairment test on all existing goodwill in the fourth quarter of each year. If facts and circumstances lead the Company’s management to believe that one of the Company’s other amortized intangible assets may be impaired, the Company will evaluate the extent to which the related cost is recoverable by comparing the future undiscounted cash flows estimated to be associated with that asset to the asset’s carrying amount and write-down that carrying amount to fair value to the extent necessary.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

The following table summarizes information relating to the Company's Other intangible assets:

	Useful Lives (Years)	June 30, 2006			December 31, 2005		
		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Unamortized indefinite life intangible assets:							
Trademarks		\$ 55,000	\$ —	\$ 55,000	\$ 55,000	\$ —	\$ 55,000
Amortized intangible assets:							
Technology	10	\$ 16,000	\$ 5,867	\$ 10,133	\$ 16,000	\$ 5,067	\$ 10,933
Patents	5-20	6,106	3,795	2,311	5,968	3,234	2,734
Customer database	5	4,200	3,080	1,120	4,200	2,660	1,540
Foam formula	10	3,700	1,357	2,343	3,700	1,172	2,528
Trademarks and other	5	3,542	2,035	1,507	3,146	1,973	1,173
Total		\$ 88,548	\$ 16,134	\$ 72,414	\$ 88,014	\$ 14,106	\$ 73,908

Amortization expense relating to intangible assets for the Company was \$1,020 and \$985 for the three months ended June 30, 2006 and June 30, 2005, respectively. For the six months ended June 30, 2006 and June 30, 2005 amortization expense relating to intangible assets was \$2,028 and \$1,960, respectively.

The changes in the carrying amount of Goodwill for the six months ended June 30, 2006 are related to changes in amounts for foreign currency translation as follows:

Balance as of December 31, 2005	\$ 199,962
Foreign currency translation adjustments and other	83
Balance as of June 30, 2006	\$ 200,045

Goodwill as of June 30, 2006 and December 31, 2005 has been allocated to the Domestic and International segments as follows:

	June 30, 2006	December 31, 2005
Domestic	\$ 89,930	\$ 89,452
International	110,115	110,510
	\$ 200,045	\$ 199,962

(k) *Software*—Preliminary project stage costs incurred are expensed and, thereafter, costs incurred in the developing or obtaining of internal use software are capitalized. Certain costs, such as maintenance and training, are expensed as incurred. Capitalized costs are amortized over a period of not more than five years and are subject to impairment evaluation in accordance with SFAS 144. Amounts capitalized for software are included in Property, plant and equipment, net.

(l) *Accrued Sales Returns*—Estimated sales returns are provided at the time of sale based on historical sales channel return rates. The Company allows product returns up to 120 days following a sale through certain sales

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

channels and on certain products. Estimated future obligations related to these products are provided by a reduction of sales in the period in which the revenue is recognized. Accrued sales returns are included in Accrued expenses and other in the accompanying Condensed Consolidated Balance Sheets.

The Company had the following activity for sales returns from December 31, 2005 to June 30, 2006:

Balance as of December 31, 2005	\$ 6,304
Amounts accrued	20,837
Returns charged to accrual	(21,700)
	<hr/>
Balance as of June 30, 2006	\$ 5,441
	<hr/>

(m) *Warranties*—The Company provides a 20-year warranty for U.S. sales and a 15-year warranty for non-U.S. sales on mattresses, each prorated for the last 10 years. The Company also provides a 2-year to 3-year warranty on pillows. Estimated future obligations related to these products are provided by charges to operations in the period in which the related revenue is recognized. Warranties are included in Accrued expenses and other in the Condensed Consolidated Balance Sheets.

The Company had the following activity for warranties from December 31, 2005 to June 30, 2006:

Balance as of December 31, 2005	\$ 3,107
Amounts accrued	1,476
Warranties charged to accrual	(1,744)
	<hr/>
Balance as of June 30, 2006	\$ 2,839
	<hr/>

(n) *Income Taxes*—Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company is regularly under audit by tax authorities around the world. The Company accrues for probable foreign and domestic tax obligations as required by facts and circumstances in the various regulatory environments.

(o) *Revenue Recognition*—Sales of products are recognized when the products are shipped to customers and the risks and rewards of ownership are transferred. No collateral is required on sales made in the normal course of business. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on historical write-off experience. The Company reviews the adequacy of its allowance for doubtful accounts quarterly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Allowance for doubtful accounts was \$4,625 and \$5,436 as of June 30, 2006 and December 31, 2005, respectively. Deposits made by customers are recorded as a liability and recognized as a sale when product is shipped. The Company had \$171 and \$454 of deferred revenue included in Accrued expenses and other in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2006 and December 31, 2005, respectively.

The Company reflects all amounts billed to customers for shipping and handling in Net sales and the costs incurred from shipping and handling product in Cost of sales. The Company no longer bills customers in the

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Domestic Retail channel for freight on large quantity orders. Amounts included in Net sales for shipping and handling were approximately \$2,457 and \$5,506 for the three months ended June 30, 2006 and June 30, 2005, respectively. For the six months ended June 30, 2006 and June 30, 2005 amounts included in Net sales for shipping and handling were approximately \$5,656 and \$12,656, respectively. Amounts included in Cost of sales for shipping and handling were approximately \$16,955 and \$19,250 for the three months ended June 30, 2006 and June 30, 2005, respectively. Amounts included in Cost of sales for shipping and handling were approximately \$34,812 and \$39,283 for the six months ended June 30, 2006 and June 30, 2005, respectively.

In connection with customer purchases financed under an extended financing program with certain third party financiers (Card Servicers), the Card Servicer pays the Company an amount equal to the total amount of such purchases, net of a non-refundable financing fee as well as an interest bearing holdback of 15% (to be released upon ultimate collection) of certain amounts financed with recourse under the program. Amounts associated with this limited program are not material to the financial statements for all periods presented.

(p) *Advertising Costs*—The Company expenses advertising costs as incurred except for production costs and advance payments, which are deferred and expensed when advertisements run for the first time. Direct response advance payments are deferred and are amortized over the life of the program. Advertising costs charged to expense were approximately \$22,732 and \$20,503 for the three months ended June 30, 2006 and June 30, 2005, respectively. For the six months ended June 30, 2006 and June 30, 2005, advertising costs charged to expense were approximately \$48,869 and \$46,283, respectively. Advertising costs deferred and included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets were approximately \$6,259 and \$6,064 as of June 30, 2006 and December 31, 2005, respectively.

(q) *Research and Development Expenses*—Research and development expenses for new products are expensed as they are incurred.

(r) *Treasury Stock*—As discussed in Note 5 below, in October 2005 Tempur-Pedic International's Board of Directors authorized a share repurchase program (Share Repurchase Program). Shares repurchased under Tempur-Pedic International's Share Repurchase Program are held in treasury for general corporate purposes, including issuances under various employee stock option plans. Treasury shares are accounted for under the cost method and reported as a reduction of Stockholders' equity. As of June 30, 2006 Tempur-Pedic International had completed its existing share repurchase authorization.

(s) *Stock Based Compensation*—The Company adopted SFAS 123R *Share-Based Payment* (SFAS 123R) on January 1, 2006 using the modified prospective method for the transition. SFAS 123R requires compensation expense relating to share-based payments be recognized in the financial statements. The cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the estimable life of the equity award. The effect of the adoption of SFAS 123R on the Company's results of operations and earnings per share was not material and is included in the Condensed Consolidated Statements of Income for the periods ended June 30, 2006. Also, in accordance with SFAS 123R, Deferred stock compensation amounts in the Stockholders' Equity section of the Condensed Consolidated Balance Sheet are included in Additional paid in capital as of June 30, 2006.

Additionally, SFAS 123R requires that the benefit of tax deductions in excess of recognized compensation expense be reported as a financing cash flow activity in the consolidated statements of cash flows. The Company had excess tax benefits related to the exercise of stock-options of \$5,140 as of June 30, 2006. Financial results including cash flows from operating results for 2005 have not been restated for the adoption of SFAS 123R.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Pro forma information in accordance with SFAS 123 for the Company for the three and six months ended June 30, 2005 is as follows:

	Three Months Ended June 30, 2005	Six Months Ended June 30, 2005
Net income as Reported	\$24,850	\$51,600
Add: Stock-based employee compensation expense included in reported net income, net of related tax benefit	724	1,566
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax benefit	(1,766)	(3,656)
Pro forma Net income	<u>\$23,808</u>	<u>\$49,510</u>
Earnings per share:		
Basic as reported	<u>\$ 0.25</u>	<u>\$ 0.52</u>
Diluted as reported	<u>\$ 0.24</u>	<u>\$ 0.50</u>
Basic—Pro forma Net income	<u>\$ 0.24</u>	<u>\$ 0.50</u>
Diluted—Pro forma Net income	<u>\$ 0.23</u>	<u>\$ 0.48</u>

In December 2005, Tempur-Pedic International accelerated the vesting of certain unvested incentive stock options which had exercise prices greater than the fair market value of the stock on the date of acceleration. Options to purchase approximately 467 shares of common stock, or approximately 18% of Tempur-Pedic International's outstanding unvested options, were subject to the acceleration. Options subject to the acceleration had exercise prices ranging from \$13.94 to \$24.40 per share and a weighted average remaining life of 9 years. The weighted average exercise price of the options subject to the acceleration was \$18.51. The purpose of the acceleration was to enable the Company to avoid recognizing compensation expense associated with these options in future periods in its financial statements, upon adoption of SFAS 123R. The acceleration resulted in an increase of \$2,842 in the pro forma employee stock option stock-based compensation expense for the fourth quarter and year ended December 31, 2005. See Note 6 for further discussion of the Company's adoption of SFAS 123R.

(2) Recently Issued Accounting Pronouncements

In May 2005, the Financial Accounting Standards Board (FASB) issued SFAS No. 154, "Accounting Changes and Error Corrections" (SFAS 154). SFAS 154 is a replacement of Accounting Principles Board No. 20, "Accounting Changes" and FASB Statement No. 3 "Reporting Accounting Changes in Interim Financial Statements." SFAS 154 provides guidance on the accounting for and reporting of accounting changes and error corrections and is effective for accounting changes and corrections of errors made in fiscal years beginning after December 31, 2005. The Company adopted this pronouncement on January 1, 2006. The adoption had no effect on the Company's Condensed Consolidated Financial Statements.

In July 2006, the FASB issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" (FIN 48), which is an interpretation of FASB Statement No. 109. FIN 48 clarifies the accounting and disclosure requirements for uncertainty in tax positions, as defined. The Company is currently evaluating the provisions of FIN 48, which is effective for fiscal years beginning after December 15, 2006.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

(3) Property, Plant and Equipment

Property, plant and equipment, net consisted of the following:

	June 30, 2006	December 31, 2005
Land and buildings	\$ 70,859	\$ 67,193
Machinery and equipment	103,956	96,298
Construction in progress	97,604	82,775
	<u>272,419</u>	<u>246,266</u>
Total accumulated depreciation	(65,900)	(53,042)
	<u>\$ 206,519</u>	<u>\$ 193,224</u>

Construction in progress is primarily comprised of the costs for the construction of the Company's New Mexico facility and includes capitalized interest costs of \$5,022 and \$2,567 as of June 30, 2006 and December 31, 2005, respectively, in connection with the construction of assets. Additionally, Construction in progress includes \$1,055 and \$843 that is included in Accounts payable as of June 30, 2006 and December 31, 2005, respectively. These amounts have been excluded from Cash flows from investing activities in the Consolidated Statements of Cash Flows in their respective periods.

(4) Long-term Debt

(a) *Long-term Debt*—Long-term debt for the Company consisted of the following:

	June 30, 2006	December 31, 2005
2005 Senior Credit Facility:		
Foreign Term Loan (EUR Denominated) payable to lenders, interest at Index Rate or LIBOR plus margin (4.46% and 3.46% as of June 30, 2006 and December 31, 2005, respectively), principal payments due quarterly through June 30, 2010 with a final payment on October 18, 2010	\$ 62,646	\$ 108,565
Domestic Long-Term Revolving Credit Facility payable to lenders, interest at Index Rate or LIBOR plus applicable margin (6.61% and 5.28% as of June 30, 2006 and December 31, 2005, respectively), commitment through and due October 18, 2010	203,500	83,000
2005 Industrial Revenue Bonds:		
Variable Rate Industrial Revenue Bonds Series 2005A, interest rate determined by remarketing agent not to exceed the lesser of (a) the highest rate under state law or (b) 12% per annum (5.36% and 4.35% as of June 30, 2006 and December 31, 2005, respectively), interest due monthly and principal due quarterly through September 1, 2030	52,005	53,925
Senior Subordinated Notes:		
U.S. Senior Subordinated Notes payable to institutional investors, interest at 10.25%, due August 15, 2010	97,500	97,500
Other:		
Mortgages payable to a bank, secured by certain property, plant and equipment and other assets, bearing fixed interest at 4.0% to 5.1%	1,483	1,491
	<u>417,134</u>	<u>344,481</u>
Less: Current portion	(22,673)	(30,770)
Long-term debt	<u>\$ 394,461</u>	<u>\$ 313,711</u>

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

(b) *Secured Credit Financing*—On October 18, 2005, Tempur-Pedic International entered into a credit agreement (the 2005 Senior Credit Facility) with Tempur-Pedic, Inc., Tempur Production USA, Inc., Dan-Foam ApS, certain other subsidiaries of Tempur-Pedic International, and Bank of America, N.A., Fifth Third Bank, Nordea Bank Danmark, A/S and Suntrust Bank. The Company used proceeds from the 2005 Senior Credit Facility to pay off amounts outstanding under its prior senior credit facility and an unsecured revolving credit facility, among other things. The prior senior credit facility was terminated upon repayment. On February 8, 2006, the Company entered into an amendment to its 2005 Senior Credit Facility, which increased availability and adjusted one of the financial covenants.

The 2005 Senior Credit Facility, as amended, consists of domestic and foreign credit facilities that provide for the incurrence of indebtedness up to an aggregate principal amount of \$390,000. The domestic credit facility is a five-year, \$260,000 revolving credit facility (Domestic Revolver). The foreign credit facilities consist of a \$20,000 revolving credit facility (Foreign Revolver) and \$110,000 term loan (Foreign Term Loan). The various credit facilities bear interest at a rate equal to the 2005 Senior Credit Facility's applicable margin, as determined in accordance with a performance pricing grid set forth in the 2005 Senior Credit Facility, plus one of the following indexes: (i) LIBOR and (ii) for U.S. dollar-denominated loans only, a base rate (defined as the higher of (a) the Bank of America prime rate and (b) the Federal Funds rate plus .50%). The Company also pays an annual facility fee on the total amount of the 2005 Senior Credit Facility. The facility fee is calculated based on the consolidated leverage ratio and ranges from .175% to .35%.

The 2005 Senior Credit Facility is guaranteed by Tempur-Pedic International, Tempur World, LLC and Tempur World Holdings, LLC, as well as certain other subsidiaries of Tempur-Pedic International, and is secured by certain fixed and intangible assets of Dan Foam ApS and substantially all the Company's U.S. assets. The maturity date of the 2005 Senior Credit Facility is October 18, 2010. The 2005 Senior Credit Facility contains certain financial covenants and requirements affecting the Company, among the most significant of which are a fixed charge coverage ratio requirement and a consolidated leverage ratio requirement. The Company was in compliance with all covenants as of June 30, 2006.

At June 30, 2006, the Company had a total of \$277,000 of long-term revolving credit facilities under the 2005 Senior Credit Facility, which was comprised of the \$257,000 Domestic Revolver and the \$20,000 Foreign Revolver (collectively, the Revolvers). The Revolvers provide for the issuance of letters of credit which, when issued, constitute usage and reduce availability under the Revolvers. The aggregate amount of letters of credit outstanding under the Revolvers was \$55,273 at June 30, 2006. After giving effect to letters of credit and \$203,500 in borrowings under the Domestic Revolver, total availability under the Revolvers was \$18,227 at June 30, 2006. There were no borrowings under the Foreign Revolver as of June 30, 2006.

(c) *Industrial Revenue Bonds*—On October 27, 2005, Tempur Production USA, Inc. (Tempur Production), a subsidiary of Tempur-Pedic International, completed an industrial revenue bond financing for the construction and equipping of Tempur Production's new manufacturing facility (the Project) located in Bernalillo County, New Mexico (Bernalillo County). Under the terms of the financing, Bernalillo County will issue up to \$75,000 of Series 2005A Taxable Variable Rate Industrial Revenue Bonds (the Series A Bonds). The Series A Bonds are marketed to third parties by a remarketing agent and secured by a letter of credit issued under the Company's Domestic Revolver and purchased by qualified investors. The Series A Bonds have a final maturity date of September 1, 2030. The interest rate on the Series A Bonds is a weekly rate set by the remarketing agent, in its sole discretion, though the interest rate may not exceed the lesser of (i) the highest rate allowed under New Mexico law or (ii) 12% per annum. On October 27, 2005, Tempur Production made an initial draw of \$53,925 on the Series A Bonds. The Company used proceeds from the Bonds to pay down the prior domestic revolving credit facility, among other things.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Bernalillo County will also issue up to \$25,000 of Series 2005B Taxable Fixed Rate Industrial Revenue Bonds (the Series B Bonds, and collectively with the Series A Bonds, the Bonds). The Series B Bonds will be sold to Tempur World LLC, will not be secured by the letter of credit described above, and will be held by Tempur World, LLC, representing the Company's equity in the Project. The Series B Bonds have a final maturity date of September 1, 2035. The interest rate on the Series B Bonds is fixed at 7.75%. On October 27, 2005, Tempur Production made an initial draw of \$17,975 under the Series B Bonds, which was transferred to and used by Tempur World LLC to purchase Series B Bonds.

On October 27, 2005, Tempur Production transferred its interest in the Project to Bernalillo County, and Bernalillo County leased the Project back to Tempur Production on a long-term basis with the right to purchase the Project for one dollar when the Bonds are retired. Pursuant to the lease agreement, Tempur Production will pay rent to Bernalillo County in an amount sufficient to pay debt service on the Bonds and certain fees and expenses. The Bonds are not general obligations of Bernalillo County, but are special, limited obligations payable solely from bond proceeds, rent paid by Tempur Production under the lease agreement, and other revenues. The substance of the transaction is that Bernalillo County issued the Bonds on behalf of Tempur Production. Therefore, the Company recorded the obligation as long-term debt of \$53,925 in its consolidated balance sheet on the date of the transaction.

(d) Senior Subordinated Notes—In 2003, Tempur-Pedic, Inc. and Tempur Production (Issuers) issued \$150,000 aggregate principal amount of 10.25% Senior Subordinated Notes due 2010 (Senior Subordinated Notes). The Senior Subordinated Notes are unsecured senior subordinated indebtedness of the Issuers and are fully and unconditionally, and jointly and severally, guaranteed on an unsecured senior subordinated basis by the Issuers' ultimate parent, Tempur-Pedic International and certain other subsidiaries of Tempur-Pedic International. Except as noted below, the Senior Subordinated Notes have no mandatory redemption or sinking fund requirements. However, the indenture governing the Senior Subordinated Notes permits the partial redemption at the Issuer's option under certain circumstances prior to August 15, 2006, and full redemption at the Issuer's option prior to August 15, 2007 at a redemption price of 100% of the principal amount plus a "make whole" premium based on the discounted value of the redemption price payable at August 15, 2007 plus remaining interest payments to such date or after August 15, 2007 at a redemption price of 105.125% of the principal amount.

If Tempur-Pedic, Inc., Tempur Production USA, Inc., Tempur-Pedic International or any of Tempur-Pedic International's other restricted subsidiaries sell certain assets or experience specific kinds of changes of control, Tempur-Pedic, Inc. and Tempur Production USA, Inc. must offer to repurchase the Senior Subordinated Notes at the prices, plus accrued and unpaid interest, and additional interest, if any, to the date of redemption specified in the indenture.

The Senior Subordinated Notes contain certain nonfinancial and financial covenants which include restrictions on: the declaration or payment of dividends and distributions; the payment, purchase, redemption, defeasance, acquisition or retirement of subordinated indebtedness; the granting of liens; the making of loans and the transfer of properties and assets; mergers; consolidations or sale of assets; the acquisition or creation of additional subsidiaries; and the sale and leaseback of assets. The Company was in compliance with all covenants as of June 30, 2006.

(5) Stockholders' Equity

(a) *Capital Stock*—Tempur-Pedic International authorized shares of capital stock are 300,000 shares of common stock and 10,000 shares of preferred stock. Subject to preferences that may be applicable to any

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

outstanding preferred stock, holders of the common stock are entitled to receive ratably such dividends as may be declared from time to time by the Board of Directors out of funds legally available for that purpose. In the event of liquidation, dissolution, or winding up, the holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding.

(b) *Share Repurchase Program*—On October 18, 2005, the Board of Directors authorized the repurchase of up to \$80,000 of Tempur-Pedic International's common stock. Share repurchases under this program were made through open market transactions, negotiated purchases or otherwise, at times and in such amounts as management deemed appropriate. During 2005, Tempur-Pedic International repurchased 6,840 shares, at a total cost of \$76,000. Tempur-Pedic International funded these share repurchases from borrowings under the 2005 Senior Credit Facility and funds from operations.

On January 25, 2006, Tempur-Pedic International's Board of Directors amended the share repurchase program described above to increase the total authorization by an additional \$100,000. On May 22, 2006, Tempur-Pedic International's Board of Directors further amended the share repurchase program to increase the total authorization under the share repurchase program by an additional \$40,000 for a total authorization to purchase up to \$220,000 of Tempur-Pedic International's common stock. During the six months ended June 30, 2006, Tempur-Pedic International repurchased 11,275 shares at a total cost of \$144,000. The share repurchases were funded from borrowings under the 2005 Senior Credit Facility and funds from operations. As of June 30, 2006, Tempur-Pedic International had completed its existing share repurchase authorization.

(6) Stock-Based Compensation

Tempur-Pedic International has two stock-based compensation plans which provide for grants of non-qualified and incentive stock options, stock appreciation rights, restricted stock and stock unit awards, performance shares, stock grants and performance based awards to employees, non-employee directors, consultants and Company advisors. The plans under which equity awards are granted are the 2002 Option Plan and the 2003 Equity Incentive Plan (the 2003 Plan). Tempur-Pedic International also has a stock-based compensation plan which permits eligible employees to purchase its shares at a discounted price, subject to certain guidelines set forth by its 2003 Employee Stock Purchase Plan (ESPP). The Company believes that awards and purchases made under these plans better align the interests of the plan participants with those of its stockholders.

The 2002 Option Plan was adopted on November 1, 2002 and provides for grants of options to purchase shares of common stock to employees and directors of the Company. Options granted under the 2002 Option Plan that qualify as incentive stock options, as defined by the Internal Revenue Code of the 1986, as amended (the Code), must have an exercise price of not less than the fair market value of Tempur-Pedic International's common stock at the date of grant. The determination of the exercise price was made by the Board of Directors. Options granted under the 2002 Option Plan provided for vesting terms as determined by the Board of Directors at the time of grant, which are generally based on 4 years of continuous service. Options can be exercised up to 10 years from the grant date and up to 5 years from the grant date for any stockholders who own 10% or more of the total combined voting power of all shares of stock of Tempur-Pedic International. The total number of shares of common stock subject to issuance under the 2002 Option Plan did not exceed 6,534 shares, which was subject to certain adjustment provisions. The Company currently anticipates there will be no additional options issued under this plan.

The 2003 Plan is administered by the Compensation Committee of the Board of Directors, which, together with the Board of Directors, has the exclusive authority to administer the 2003 Plan, including the power to

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

determine eligibility to receive awards, the types and number of shares of stock subject to the awards, the price and timing of awards and the acceleration or waiver of any vesting and performance of forfeiture restrictions, in each case subject to the terms of the 2003 Plan. Any of the Company's employees, non-employee directors, consultants and Company advisors, as determined by the Compensation Committee, may be selected to participate in the 2003 Plan. The 2003 Plan provides for awards of stock options, stock appreciation rights, restricted stock and stock unit awards, performance shares, stock grants and performance based awards. The awards generally vest based on 4 years of continuous service and have 10-year contractual terms. Tempur-Pedic International may issue a maximum of 8,000 shares of its common stock under the 2003 Plan.

The ESPP permits eligible employees to purchase up to certain limits as defined in the 2003 ESPP of Tempur-Pedic International's common stock annually over the course of two semi-annual offering periods at a price of no less than 85% of the price per share of Tempur-Pedic International's common stock either at the beginning or the end of each six-month offering period, whichever is less. The Compensation Committee of the Board of Directors administers the 2003 ESPP. The Board of Directors may amend or terminate the 2003 ESPP. The 2003 ESPP is intended to comply with the requirements of Section 423 of the Code. Tempur-Pedic International may issue a maximum of 500 shares of its common stock under the 2003 ESPP.

Effective January 1, 2006, the Company adopted the provisions of SFAS 123R. The Company uses the Black-Scholes option pricing model to calculate the fair value of options granted which are subject to SFAS 123R. The Company also used this pricing model for all periods prior to the adoption of SFAS 123R to disclose the pro forma information regarding net income and earnings per share as required by SFAS 123, which also required that the information be determined as if the Company had accounted for its stock options granted subsequent to December 31, 2002 under the fair value method of SFAS 123.

The assumptions used in the Black-Scholes pricing model for the three and six months ended June 30, 2006 and June 30, 2005 are set forth in the following table. Expected volatility is based on the historical volatility of Tempur-Pedic International's common stock. The expected life of the options represents the period of time that the Company expects the options granted to be outstanding. The risk-free rate is based on the expected yield of the option over the period during its contractual life. The assumptions used in the Black-Scholes pricing model for the three and six months ended June 30, 2006 and June 30, 2005 are as follows:

	Six Months Ended June 30,	
	2006	2005
Expected volatility of stock	46%	33%
Expected life of option, range in years	5 – 6.1	5
Risk-free interest rate	3%	3%
Expected dividend yield on stock	0%	0%

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility. Tempur-Pedic International's options have had characteristics significantly different from those of similar traded options, and changes in the subjective input can materially affect the fair value estimate.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

A summary of stock options activity under the 2002 Option Plan and 2003 Plan for the six months ended June 30, 2006 is presented below:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2005	5,979	\$ 5.13		\$
Granted	1,360	13.53		
Exercised	(1,655)	1.73		
Forfeited or expired	(89)	6.27		
Options outstanding at June 30, 2006	5,595	\$ 8.19	8.13	\$ 29,744
Options exercisable at June 30, 2006	2,094	\$ 6.76		\$ 14,123

The total intrinsic value of options exercised during the three months ended June 30, 2006 and June 30, 2005 was \$19,893 and \$7,476, respectively. For the six months ended June 30, 2006 and June 30, 2005 the total intrinsic value of options exercised was \$20,994 and \$14,102, respectively. During the three and six months ended June 30, 2006 and June 30, 2005, there were 1,360 and 75 options granted, respectively.

A summary of Tempur-Pedic International's unvested shares as of June 30, 2006, and changes during the six months ended June 30, 2006, is presented below:

	Shares	Weighted Average Grant Date Fair Value
Options unvested at December 31, 2005	3,344	\$ 4.75
Granted	1,360	13.53
Vested	(1,014)	1.78
Forfeited	89	6.27
Options unvested at June 30, 2006	3,779	\$ 8.83

The Black-Scholes pricing model amortizes compensation expenses on a "straight-line" basis, and the expense is expected to be recognized over a weighted-average period of 4.0 years. The total fair value of shares vested during the three months ended June 30, 2006 and June 30, 2005 was \$6,898 and \$10,875, respectively. The total fair value of shares vested during the six months ended June 30, 2006 and June 30, 2005 was \$14,605 and \$21,280, respectively. For the three and six months ended June 30, 2006, the Company recognized \$299 and \$598 of stock-based compensation expense in General and administrative expenses related to stock options granted under the 2003 Plan which were subject to SFAS 123R. As of June 30, 2006, there was \$10,701 of unearned stock-based compensation expense related to these options. The future amortization of these unearned stock-based compensation costs will be \$1,554 for the remainder of 2006, \$3,061 in 2007, \$3,061 in 2008 and \$3,025 in 2009.

The Company recorded \$307 and \$688 of stock-based compensation expense for the three and six months ended June 30, 2006, respectively, related to options granted under the 2002 Option Plan prior to the initial public offering in 2003 that have exercise prices that are less than the deemed market value of the underlying common stock at the date of grant. As of June 30, 2006, there was \$632 of unearned stock-based compensation expense. The resulting unearned stock-based compensation is amortized to compensation expense over the respective vesting term, based on the "graded vesting" methodology. The future amortization of these unearned stock-based compensation costs will be \$418 for the remainder of 2006 and \$214 in 2007.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

For the three and six months ended June 30, 2006, the Company recognized \$110 and \$219, respectively, of stock-based compensation expense related to restricted stock units (RSUs) granted in December 2004. As of June 30, 2006, there was \$657 of unearned stock-based compensation expense related to the RSUs. The resulting unearned stock-based compensation is amortized to compensation expense over the respective vesting term on a “straight-line” basis. The future amortization of these unearned stock-based compensation costs will be \$219 for the remainder of 2006 and \$438 in 2007.

Cash received from options exercised under all stock-based compensation plans, including cash received from options issued from treasury shares, for the three months ended June 30, 2006 and June 30, 2005 was \$2,657 and \$1,007, respectively. Cash received from options exercised under all stock-based compensation plans, including cash received from options issued from treasury shares, for the six months ended June 30, 2006 and June 30, 2005 was \$2,851 and \$1,697, respectively.

(7) Accumulated Other Comprehensive Income

The components of Accumulated other comprehensive income are as follows:

	June 30, 2006	December 31, 2005
Financial instruments accounted for as hedges	\$ (496)	\$ (478)
Foreign currency translation	2,789	1,615
Accumulated other comprehensive income	<u>\$2,293</u>	<u>\$ 1,137</u>

(8) Commitments and Contingencies

(a) *Purchase Commitments*—As of June 30, 2006, the Company had outstanding commitments of approximately \$3,127 of capital expenditures, primarily related to the construction of the production facility in Albuquerque, New Mexico. The Company will, from time to time, enter into limited purchase commitments for the purchase of certain raw materials. Amounts committed under these programs are not significant as of June 30, 2006.

(b) *Securities Litigation*—Between October 7, 2005 and November 21, 2005, five complaints were filed against Tempur-Pedic International and certain of its directors and officers in the United States District Court for the Eastern District of Kentucky (Lexington Division) purportedly on behalf of a class of shareholders who purchased Tempur-Pedic International’s stock between April 22, 2005 and September 19, 2005. On December 29, 2005, the court consolidated these five actions (the Securities Law Action). Lead plaintiffs filed a consolidated complaint on February 27, 2006. In their consolidated complaint, lead plaintiffs assert claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Lead plaintiffs allege that certain of Tempur-Pedic International’s public disclosures regarding its financial performance between April 22, 2005 and September 19, 2005 were false and/or misleading. The principal allegation set forth in the Securities Law Action is that Tempur-Pedic International did not disclose the impact of competition on its prospects. The plaintiffs seek compensatory damages, costs, fees and other relief within the Court’s discretion. On June 14, 2006, the Company filed a motion to dismiss all claims in the Securities Law Action. That motion is currently pending before the Court. The Company strongly believes that the Securities Law Action lacks merit, and the Company intends to defend against the claims vigorously. However, due to the inherent uncertainties of litigation, the Company cannot predict the outcome of the Securities Law Action at this time, and the Company can give no assurance that these claims will not have a material adverse affect on our financial position or results of operations.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

On November 10, 2005 and December 15, 2005, complaints were filed in the state courts of Delaware and Kentucky, respectively, against certain officers and directors of Tempur-Pedic International purportedly derivatively on behalf of Tempur-Pedic International (the Derivative Complaints). The Derivative Complaints assert that the named officers and directors breached their fiduciary duties when they allegedly sold Tempur-Pedic International's securities on the basis of material non-public information in 2005. The Delaware Derivative Complaint also asserts a claim for breach of fiduciary duty with respect to the disclosures that also are the subject of the Securities Law Action described above. On December 14, 2005 and January 26, 2006, respectively, the Delaware court and Kentucky court stayed these derivative actions pending the outcome of the motion to dismiss that defendants have filed in the Securities Law Action. Tempur-Pedic International is also named as a nominal defendant in the Derivative Complaints, although the actions are derivative in nature and purportedly asserted on behalf of Tempur-Pedic International. Tempur-Pedic International is in the process of evaluating these claims.

The Company is also party to various other legal proceedings generally incidental to its business. Although the ultimate disposition of these proceedings is not presently determinable, management does not believe that adverse determinations in any or all of such proceedings will have a materially adverse effect upon the financial condition, liquidity or results of operations of the Company.

(9) Income Taxes

The Company's effective tax rate for the six months ended June 30, 2006 was 36.6%. For the same period in 2005, the effective tax rate was 38.1%. The decrease in effective tax rate is primarily attributable to a compensation expense benefit associated with certain options granted prior to the initial public offering and exercised during the second quarter of 2006. In addition, the Company received a favorable state tax ruling in the fourth quarter of 2005 that reduced its state tax expense.

Reconciling items between the federal statutory income tax rate of 35.0% and the effective tax rate include state income taxes, differences in U.S. statutory rates and foreign tax rates, foreign income currently taxable in the U.S., compensation expense associated with certain options granted, production activities deduction, and certain other permanent differences.

At June 30, 2006, Tempur-Pedic International had remaining undistributed earnings of \$8,356 from its foreign subsidiaries determined under U.S. tax principles as of November 1, 2002 related to the period prior to the acquisition of Tempur World Inc. by Tempur-Pedic International translated into U.S. dollars at the applicable exchange rate on June 30, 2006. All pre-acquisition earnings of \$60,810 related to Dan Foam ApS were distributed as part of the \$155,650 repatriation plan under the Jobs Creation Act in 2005. The remaining balance of \$8,356 relates to other foreign subsidiaries. No provisions have been made for U.S. income taxes or foreign withholding taxes on the remaining \$8,356 of undistributed earnings, as these earnings are considered indefinitely reinvested.

In addition, Tempur-Pedic International had remaining undistributed earnings from its foreign subsidiaries determined under U.S. generally accepted accounting principles for the period November 1, 2002 through June 30, 2006 of \$96,600. No provisions have been made for U.S. income taxes or foreign withholding taxes on the remaining \$96,600 of undistributed earnings, as these earnings are considered indefinitely reinvested.

(10) Major Customers

Five customers accounted for approximately 16% and 11% of the Company's sales for the three months ended June 30, 2006 and June 30, 2005, respectively. These same customers also accounted for approximately

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

16% of accounts receivable as of both June 30, 2006 and June 30, 2005. Five customers accounted for approximately 13% and 10% of the Company's sales for the six months ended June 30, 2006 and June 30, 2005, respectively. These same customers also accounted for approximately 16% and 15% of accounts receivable as of June 30, 2006 and June 30, 2005. The loss of one or more of these customers could negatively impact the Company. The composition of our top 5 customers varies between the periods ended June 30, 2006 and June 30, 2005.

(11) Earnings Per Share

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Numerator:				
Net income	\$ 26,112	\$ 24,850	\$ 53,005	\$ 51,600
Denominator:				
Denominator for basic earnings per share-weighted average shares	84,377	98,791	86,848	98,607
Effect of dilutive securities:				
Employee stock options	3,083	4,640	3,398	4,708
Denominator for basic earnings per share-adjusted weighted average shares	<u>87,460</u>	<u>103,431</u>	<u>90,246</u>	<u>103,315</u>
Basic earnings per share	<u>\$ 0.31</u>	<u>\$ 0.25</u>	<u>\$ 0.61</u>	<u>\$ 0.52</u>
Diluted earnings per share	<u>\$ 0.30</u>	<u>\$ 0.24</u>	<u>\$ 0.59</u>	<u>\$ 0.50</u>

(12) Business Segment Information

The Company operates in two business segments: Domestic and International. These reportable segments are strategic business units that are managed separately based on the fundamental differences in their operations. The Domestic segment consists of the U.S. manufacturing facility, whose customers include the U.S. distribution subsidiary and certain North American third party distributors. The International segment consists of the manufacturing facility in Denmark, whose customers include all of the distribution subsidiaries and third party distributors outside the Domestic segment. The Company evaluates segment performance based on Net sales and Operating income.

The following table summarizes Total assets by segment:

	June 30, 2006	December 31, 2005
Total assets:		
Corporate	\$ 593,949	\$ 372,341
Domestic	673,663	493,871
International	300,512	301,465
Intercompany eliminations	(851,521)	(465,366)
	<u>\$ 716,603</u>	<u>\$ 702,311</u>

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

The following tables summarize other segment information:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Net sales from external customers:				
Corporate	\$ —	\$ —	\$ —	\$ —
Domestic	142,665	124,054	294,181	271,984
International	76,297	68,561	153,367	143,010
	<u>\$ 218,962</u>	<u>\$ 192,615</u>	<u>\$ 447,548</u>	<u>\$ 414,994</u>
Inter-segment sales:				
Corporate	\$ —	\$ —	\$ —	—
Domestic	—	—	—	—
International	785	11,514	1,414	23,914
Intercompany eliminations	(785)	(11,514)	(1,414)	(23,914)
	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>
Operating income/(loss):				
Corporate	\$ (3,984)	\$ (3,430)	\$ (7,507)	\$ (7,702)
Domestic	30,919	27,062	59,687	60,626
International	20,327	20,965	42,299	41,053
	<u>\$ 47,262</u>	<u>\$ 44,597</u>	<u>\$ 94,479</u>	<u>\$ 93,977</u>
Depreciation and amortization (excluding stock-based compensation amortization):				
Corporate	\$ 129	\$ 109	\$ 254	\$ 213
Domestic	3,231	2,838	6,388	5,752
International	2,908	3,113	5,731	6,625
	<u>\$ 6,268</u>	<u>\$ 6,060</u>	<u>\$ 12,373</u>	<u>\$ 12,590</u>

The following table sets forth Net sales by significant product group:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Mattresses	\$ 149,870	\$ 130,788	\$ 309,785	\$ 284,880
Pillows	29,050	28,579	57,529	61,910
All other	40,042	33,248	80,234	68,204
	<u>\$ 218,962</u>	<u>\$ 192,615</u>	<u>\$ 447,548</u>	<u>\$ 414,994</u>

During the course of normal operations, the Domestic segment may purchase inventory from the Danish manufacturing facility from time to time. These purchases are included in the International segment as Intercompany sales. The Intercompany profits on these sales are eliminated from the International segment when the manufacturing profit in ending finished goods inventory is eliminated during the consolidation of the Company's results. These manufacturing profits were \$146 and \$1,692 for the three months ended June 30, 2006 and June 30, 2005, respectively, and \$289 and \$3,439 for the six months ended June 30, 2006 and June 30, 2005, respectively.

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

(13) Condensed Consolidating Interim Financial Information

On August 15, 2003, the Issuers issued \$150,000 aggregate principal amount of Senior Subordinated Notes. Approximately \$97,500 aggregate principal amount of Senior Subordinated Notes remain outstanding. The Senior Subordinated Notes are unsecured senior subordinated indebtedness of the Issuers and are fully and unconditionally, and jointly and severally, guaranteed on an unsecured senior subordinated basis by the Issuers' ultimate parent, Tempur-Pedic International, and two intermediate parent corporations (referred to as the Combined Guarantor Parents) and all of Tempur-Pedic International's current and future domestic subsidiaries (referred to collectively as the Combined Guarantor Subsidiaries), other than the Issuers. The Issuers and subsidiary guarantors are indirectly 100% owned subsidiaries of the Combined Guarantor Parents and the subsidiary guarantors are 100% owned subsidiaries of the Issuers. The foreign subsidiaries (referred to as Combined Non-Guarantor Subsidiaries) represent the foreign operations of the Company and will not guarantee this debt. The following financial information presents Condensed Consolidating Balance Sheets, Statements of Income, and Statements of Cash Flows for the Combined Guarantor Parents, Issuers and their Subsidiary Guarantors and Combined Non-Guarantor Subsidiaries.

Condensed Consolidating Statements of Income
For the Three Months Ended June 30, 2006
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Net sales	\$ —	\$ 551	\$ —	\$ 142,114	\$ 77,082	\$ (785)	\$ 218,962
Cost of goods sold	—	19	(318)	79,514	34,016	(785)	112,446
Gross profit	—	532	318	62,600	43,066	—	106,516
Operating expenses	1,099	4,854	3,203	27,359	22,739	—	59,254
Operating income (loss)	(1,099)	(4,322)	(2,885)	35,241	20,327	—	47,262
Interest income (expense), net	(1,330)	(4,036)	89	28	(968)	—	(6,217)
Other income (loss)	(11)	26,171	(47)	(26,265)	97	—	(55)
Loss on extinguishment of debt	—	—	—	—	—	—	—
Income taxes	—	8,761	(697)	761	6,053	—	14,878
Net income (loss)	\$(2,440)	\$ 9,052	\$ (2,146)	\$ 8,243	\$ 13,403	\$ —	\$ 26,112

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Condensed Consolidating Statements of Income
For the Three Months Ended June 30, 2005
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Net sales	\$ —	\$ 2,129	\$ —	\$ 121,925	\$ 80,075	\$ (11,514)	\$ 192,615
Cost of goods sold	—	961	(271)	66,422	38,482	(11,514)	94,080
Gross profit	—	1,168	271	55,503	41,593	—	98,535
Operating expenses	1,035	3,670	2,666	25,939	20,628	—	53,938
Operating income (loss)	(1,035)	(2,502)	(2,395)	29,564	20,965	—	44,597
Interest income (expense), net	—	(3,851)	(1,064)	5	46	—	(4,864)
Other income (loss)	13	23,131	191	(23,078)	155	—	412
Income taxes	—	7,170	(892)	1,587	7,430	—	15,295
Net income (loss)	\$(1,022)	\$ 9,608	\$ (2,376)	\$ 4,904	\$ 13,736	\$ —	\$ 24,850

Condensed Consolidating Statements of Income
For the Six Months Ended June 30, 2006
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Net sales	\$ —	\$ 1,598	\$ —	\$ 292,583	\$ 154,781	\$ (1,414)	\$ 447,548
Cost of goods sold	—	630	(654)	164,057	67,159	(1,414)	229,778
Gross profit	—	968	654	128,526	87,622	—	217,770
Operating expenses	2,313	9,859	5,848	59,947	45,324	—	123,291
Operating income (loss)	(2,313)	(8,891)	(5,194)	68,579	42,298	—	94,479
Interest income (expense), net	(1,435)	(7,860)	594	28	(2,001)	—	(10,674)
Other income (loss)	(15)	52,418	(107)	(52,551)	107	—	(148)
Loss on extinguishment of debt	—	—	—	—	—	—	—
Income taxes	—	17,851	(889)	998	12,692	—	30,652
Net income (loss)	\$(3,763)	\$ 17,816	\$ (3,818)	\$ 15,058	\$ 27,712	\$ —	\$ 53,005

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Condensed Consolidating Statements of Income
For the Six Months Ended June 30, 2005
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Net sales	\$ —	\$ 4,483	\$ —	\$ 267,501	\$ 166,924	\$ (23,914)	\$ 414,994
Cost of goods sold	—	2,163	(593)	143,510	81,050	(23,914)	202,216
Gross profit	—	2,320	593	123,991	85,874	—	212,778
Operating expenses	2,743	9,070	5,552	56,615	44,821	—	118,801
Operating income (loss)	(2,743)	(6,750)	(4,959)	67,376	41,053	—	93,977
Interest income (expense), net	—	(7,740)	(2,056)	11	(442)	—	(10,227)
Other income (loss)	15	49,435	347	(49,861)	391	—	327
Loss on extinguishment of debt	—	—	—	—	(717)	—	(717)
Income taxes	—	16,572	(1,434)	3,386	13,236	—	31,760
Net income (loss)	\$(2,728)	\$ 18,373	\$ (5,234)	\$ 14,140	\$ 27,049	\$ —	\$ 51,600

Condensed Consolidating Balance Sheets
As of June 30, 2006
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Current assets	\$ 1,074	\$ 231,661	\$ 3,742	\$ 69,492	\$ 106,158	\$ (181,471)	\$ 230,656
Property, plant and equipment, net	—	142,582	327	6,132	57,480	(2)	206,519
Other noncurrent assets	237,205	299,420	351,602	—	136,875	(745,674)	279,428
Total assets	\$ 238,279	\$ 673,663	\$ 355,671	\$ 75,624	\$ 300,513	\$ (927,147)	\$ 716,603
Current liabilities	\$ 154,335	\$ (6,576)	\$ 8,438	\$ 90,207	\$ 71,017	\$ (181,472)	\$ 135,949
Noncurrent liabilities	1	610,201	88,508	—	199,172	(463,439)	434,443
Equity (deficit)	83,943	70,038	258,725	(14,583)	30,324	(282,236)	146,211
Total liabilities and equity (deficit)	\$ 238,279	\$ 673,663	\$ 355,671	\$ 75,624	\$ 300,513	\$ (927,147)	\$ 716,603

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Condensed Consolidating Balance Sheets
As of December 31, 2005

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Current assets	\$ 647	\$ 76,888	\$ 19,917	\$ 56,428	\$ 107,156	\$ (32,768)	\$ 228,268
Property, plant and equipment, net	—	130,608	472	5,543	56,601	—	193,224
Other noncurrent assets	132,997	286,374	218,308	1,967	137,707	(496,534)	280,819
Total assets	\$ 133,644	\$ 493,870	\$ 238,697	\$ 63,938	\$ 301,464	\$ (529,302)	\$ 702,311
Current liabilities	\$ 15,866	\$ (25,446)	\$ 19,297	\$ 80,072	\$ 63,957	\$ (32,767)	\$ 120,979
Noncurrent liabilities	—	482,170	89,327	50	236,060	(452,604)	355,003
Equity (deficit)	117,778	37,146	130,073	(16,184)	1,447	(43,931)	226,329
Total liabilities and equity (deficit)	\$ 133,644	\$ 493,870	\$ 238,697	\$ 63,938	\$ 301,464	\$ (529,302)	\$ 702,311

Condensed Consolidating Statements of Cash Flows
For the Six Months Ended June 30, 2006
(Unaudited)

	Ultimate Parent	Combined Issuer Subsidiaries	Combined Guarantor Parents	Combined Guarantor Subsidiaries	Combined Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
Net (loss) income	\$ (3,763)	\$ 17,816	\$ (3,818)	\$ 15,058	\$ 27,712	\$ —	\$ 53,005
Non-cash expenses	1,520	6,555	(312)	387	6,167	22	14,339
Changes in working capital	138,114	(121,973)	4,579	(16,040)	14,508	(22)	19,166
Net cash (used in) / provided by operating activities	135,871	(97,602)	449	(595)	48,387	—	86,510
Net cash used for investing activities	—	(17,723)	(590)	595	(1,315)	—	(19,033)
Net cash provided by / (used in) financing activities	(136,024)	118,167	(26)	—	(53,121)	—	(71,004)
Effect on exchange rate changes on cash	—	—	—	—	1,484	—	1,484
Net (decrease) increase in cash and cash equivalents	(153)	2,842	(167)	—	(4,565)	—	(2,043)
Cash and cash equivalents at beginning of period	451	2,044	502	—	14,858	—	17,855
Cash and cash equivalents at end of period	\$ 298	\$ 4,886	\$ 335	\$ —	\$ 10,293	\$ —	\$ 15,812

TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)—(Continued)
(In thousands, except per share amounts)

Condensed Consolidating Statements of Cash Flows
For the Six Months Ended June 30, 2005
(Unaudited)

	<u>Ultimate Parent</u>	<u>Combined Issuer Subsidiaries</u>	<u>Combined Guarantor Parents</u>	<u>Combined Guarantor Subsidiaries</u>	<u>Combined Non- Guarantor Subsidiaries</u>	<u>Consolidating Adjustments</u>	<u>Consolidated</u>
Net (loss) income	\$(2,728)	\$ 18,373	\$ (5,234)	\$ 14,140	\$ 27,049	\$ —	\$ 51,600
Non-cash expenses	1,634	6,588	264	1,051	7,240	—	16,777
Changes in working capital	(1,136)	(15,474)	5,804	(14,472)	6,025	—	(19,253)
Net cash (used in) / provided by operating activities	(2,230)	9,487	834	719	40,314	—	49,124
Net cash used for investing activities	—	(44,346)	(1,278)	(938)	(3,120)	—	(49,682)
Net cash provided by / (used in) financing activities	1,712	34,246	333	—	(30,870)	—	5,421
Effect on exchange rate changes on cash	—	—	—	—	(5,063)	—	(5,063)
Net (decrease) increase in cash and cash equivalents	(518)	(613)	(111)	(219)	1,261	—	(200)
Cash and cash equivalents at beginning of period	970	551	607	219	26,021	—	28,368
Cash and cash equivalents at end of period	\$ 452	\$ (62)	\$ 496	\$ —	\$ 27,282	\$ —	\$ 28,168

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes thereto included herein. The forward-looking statements in this discussion regarding the mattress and pillow industries, our expectations regarding our future performance, liquidity and capital resources and other non-historical statements in this discussion include numerous risks and uncertainties, as described under "Special Note Regarding Forward-Looking Statements" and "Risk Factors" elsewhere in this quarterly report on Form 10-Q. Our actual results may differ materially from those contained in any forward-looking statements. Except as may be required by law, we undertake no obligation to publicly update or revise any of the forward-looking statements contained herein.

Executive Overview

General—We are the leading global manufacturer, marketer and distributor of premium mattresses and pillows, which we sell globally in over 70 countries under the TEMPUR® and Tempur-Pedic® brands. We believe our premium mattresses and pillows are more comfortable than standard bedding products because our proprietary, pressure-relieving TEMPUR® material is temperature sensitive, has a high density, and conforms to the body to therapeutically align the neck and spine, thus reducing neck and lower back pain, two of the most common complaints about other sleep surfaces.

Business Segment Information—We have two operating business segments: Domestic and International. These reportable segments are strategic business units that are managed separately. The Domestic operating segment consists of our U.S. manufacturing facility whose customers include our U.S. distribution subsidiary and certain North, Central, and South American third party distributors. The International operating segment consists of our manufacturing facility in Denmark, whose customers include all of our distribution subsidiaries and third party distributors outside the Domestic segment. We evaluate segment performance based on Net sales and Operating income. For the purpose of this Management's Discussion and Analysis of Financial Condition and Results of Operations, our Corporate office operating expenses and certain amounts relating to Goodwill and other assets that are carried at the holding company level are included in the Domestic operating segment.

Strategy and Outlook

Our goal is to be the global leader in the bedding industry. In order to achieve this goal, we expect to continue to pursue certain key strategies in 2006:

- Maintain our focus primarily on premium mattresses and pillows and to regularly introduce new products.
- Continue to invest in increasing our global brand awareness through targeted marketing and advertising campaigns that further associate our brand name with better overall sleep and premium quality products.
- Continue to extend our presence on a targeted basis in retail stores in both the U.S. and International segments.
- Continue to invest in our operating infrastructure to meet the requirements of our growing business, including increases in our research and development capacity.

Results of Operations

Key financial highlights for the first six months of 2006 include the following:

- Net sales rose 14% to \$219.0 million from \$192.6 million in the second quarter of 2005. Retail channel Net sales increased 21%. Sales in the U.S. furniture Retail channel were especially strong, with an increase of 29%. Sales in the International Retail channel increased 19%.

Table of Contents

- Earnings per share (EPS) rose 25% to \$0.30 per diluted share in the second quarter of 2006 from \$0.24 per diluted share in the second quarter of 2005. Share repurchases completed in the second quarter of 2006 contributed less than half a cent to second quarter 2006 fully diluted EPS.
- In the second quarter of 2006, International mattress unit growth increased 11% over the second quarter of 2005. Domestic mattress unit growth was especially strong, increasing 22% for the same periods.
- Cash flow provided by operations increased to \$35.0 million for the six months ended June 30, 2006 from \$15.0 million for the same period for 2005. The increase was principally driven by improved working capital. For the six months ended June 30, 2006, cash flow provided by operations increased to \$86.5 million from \$49.1 million for the six months ended June 30, 2005.
- We made a voluntary prepayment of \$20.5 million on our European term loan, in excess of our scheduled principal payment of \$4.9 million, for a total principal reduction of \$25.4 million. This is the second consecutive quarter during which we have made a voluntary prepayment in excess of \$20.0 million on our European term loan. For the six months ended June 30, 2006, we have voluntarily prepaid \$42.3 million on our European term loan.
- During the second quarter, Tempur-Pedic International purchased 3.3 million shares of its common stock at a total cost of \$45.8 million. These purchases were funded primarily by increased borrowings under our domestic revolving credit facility.

(In millions, except earnings per share)	Three Months Ended June 30,				Six Months Ended June 30,			
	2006		2005		2006		2005	
Net sales	\$ 219.0	100%	\$ 192.6	100%	\$ 447.6	100%	\$ 415.0	100%
Cost of sales	112.5	51	94.1	49	229.8	51	202.2	49
Gross profit	106.5	49	98.5	51	217.8	49	212.8	51
Selling and marketing expenses	40.3	18	38.1	20	85.1	19	83.1	20
General and administrative and other	18.9	9	15.8	8	38.2	9	35.7	8
Operating income	47.3	22	44.6	23	94.5	21	94.0	23
Interest expense, net	(6.2)	(3)	(4.9)	(2)	(10.7)	(2)	(10.2)	(3)
Loss on extinguishment of debt	—	—	—	—	—	—	(0.7)	—
Other income (expense), net	(0.1)	—	0.4	—	(0.1)	—	0.3	—
Income before income taxes	41.0	19	40.1	21	83.7	19	83.4	20
Income tax provision	14.9	7	15.3	8	30.7	7	31.8	8
Net income	\$ 26.1	12%	\$ 24.8	13%	\$ 53.0	12%	\$ 51.6	12%
Earnings per share:								
Basic	\$ 0.31		\$ 0.25		\$ 0.61		\$ 0.52	
Diluted	\$ 0.30		\$ 0.24		\$ 0.59		\$ 0.50	
Weighted average shares outstanding:								
Basic	84,377		98,792		86,848		98,607	
Diluted	87,460		103,431		90,246		103,315	

Three Months Ended June 30, 2006 Compared with Three Months Ended June 30, 2005

We generate sales through four distribution channels: Retail, Direct, Healthcare and Third party. The Retail channel sells to furniture, specialty and department stores. The Direct channel sells directly to consumers. The Healthcare channel sells to hospitals, nursing homes, healthcare professionals and medical retailers. The Third

[Table of Contents](#)

party channel sells to distributors in countries where we do not operate our own distribution subsidiaries. The following table sets forth Net sales information, by channel, for the periods indicated:

	CONSOLIDATED		DOMESTIC		INTERNATIONAL	
	Three Months Ended June 30,		Three Months Ended June 30,		Three Months Ended June 30,	
	2006	2005	2006	2005	2006	2005
<i>(Millions)</i>						
Retail	\$ 173.3	\$ 143.7	\$ 117.7	\$ 97.1	\$ 55.6	\$ 46.6
Direct	20.4	26.1	18.1	22.2	2.3	3.9
Healthcare	10.2	10.6	2.9	2.6	7.3	8.0
Third Party	15.1	12.2	4.0	2.2	11.1	10.0
	\$ 219.0	\$ 192.6	\$ 142.7	\$ 124.1	\$ 76.3	\$ 68.5
Domestic	\$ 142.7	\$ 124.1				
International	76.3	68.5				
Total	\$ 219.0	\$ 192.6				

A summary of Net sales by product is below:

	CONSOLIDATED		DOMESTIC		INTERNATIONAL	
	Three Months Ended June 30,		Three Months Ended June 30,		Three Months Ended June 30,	
	2006	2005	2006	2005	2006	2005
<i>(Millions)</i>						
Net sales:						
Mattresses	\$ 149.9	\$ 130.7	\$ 105.3	\$ 91.0	\$ 44.6	\$ 39.7
Pillows	29.0	28.7	12.5	12.1	16.5	16.6
Other	40.1	33.2	24.9	21.0	15.2	12.2
	\$ 219.0	\$ 192.6	\$ 142.7	\$ 124.1	\$ 76.3	\$ 68.5
Units sold ⁽¹⁾:						
Mattresses	178,742	152,837	105,115	86,436	73,627	66,401
Pillows	575,044	585,257	244,280	252,327	330,764	332,930

⁽¹⁾ Units sold represent Net sales after consideration of returned mattresses and pillows and excludes units shipped to fulfill warranty claims and promotion activities.

Net sales. Net sales for the three months ended June 30, 2006 increased to \$219.0 million from \$192.6 million for the same period in 2005, an increase of \$26.4 million, or 14%. This increase was primarily attributable to an increase in mattress sales in our Retail channel. Mattress sales increased \$19.2 million, or 15%. For the three months ended June 30, 2006, our Retail channel Net sales increased to \$173.3 million from \$143.7 million for the same period in 2005, an increase of \$29.6 million, or 21%. As our Retail channel has expanded, Net sales have also been positively impacted by a reduction in our sales returns as a percentage of our Net sales. The Retail channel typically experiences a lower return rate than our Direct channel.

Our Third Party channel Net sales increased by 24%, which was due primarily to growth in our Canadian and other third party distributors in our Domestic segment. Consolidated pillow sales increased approximately \$0.3 million or 1% from the second quarter of 2005. Our Direct and Healthcare channel Net sales declined 22% and 4%, respectively. The Direct channel decline is due primarily to the growth in our Retail channel in the Domestic and International segments, which is consistent with our strategy to expand distribution for our products into targeted retail stores. We also decided to focus our International direct model in the U.K. only.

[Table of Contents](#)

Domestic. Domestic Net sales for the three months ended June 30, 2006 increased to \$142.7 million from \$124.1 million for the same period in 2005, an increase of \$18.6 million, or 15%. Our Domestic Retail channel continues to be our largest channel, with \$117.7 million in Net sales for the three months ended June 30, 2006. This is an increase of \$20.6 million, or 21% over the prior year quarter. This increase is primarily due to our efforts to target select retail furniture accounts. Our Third Party channel Net sales increased 82% due to our continued market share growth in Canada and in certain Central and South American countries. Our Direct channel Net sales decreased 18%. Domestic mattress sales in the second quarter of 2006 increased \$14.3 million, or 16%, over the same period in 2005. In addition, pillow sales increased \$0.4 million, or 3%.

International. International Net sales for the three months ended June 30, 2006 increased to \$76.3 million from \$68.5 million for the same period in 2005, an increase of \$7.8 million, or 11%. The largest channel in our International segment continues to be our Retail channel, which increased \$9.0 million, or 19%, for the three months ended June 30, 2006. Our Direct channel Net sales decreased 41%, primarily attributable to our decision to focus our International direct model in the U.K. only. Our Third party sales increased 11%, primarily due to our international market share gains. In addition, our Healthcare channel Net sales decreased \$0.7 million, or 9%. International mattress sales in the first quarter of 2006 increased \$4.9 million, or 12%, over the second quarter of 2005. Pillow sales for the second quarter of 2006 decreased \$0.1 million, or 1%, as compared to the second quarter of 2005. The decrease in pillow sales is primarily related to our efforts to limit unauthorized sales by third parties into certain existing markets in Asia.

Gross profit. Gross profit for the three months ended June 30, 2006 increased to \$106.5 million from \$98.5 million for the same period in 2005, an increase of \$8.0 million, or 8%. Our margins are impacted by the relative rate of growth in our Retail channel. Sales in our Retail channel are generally at wholesale prices. The overall shift in our product mix to mattresses and other products is also a factor because our mattresses generally carry lower margins than our pillows and are sold with lower margin products such as foundations and bed frames. Increases in raw material costs have impacted our gross margin. However, our ongoing productivity and global sourcing initiatives have mitigated the impact of these cost increases to date. We currently expect our gross margins to improve as a result of these initiatives during the second half of 2006 as compared to the first half of the year.

Our gross margin can be negatively impacted as a result of opening certain new Retail customer accounts and the rollout of new mattress offerings. We provide discounted floor models to certain new Retail customers and on new mattresses, which can temporarily reduce our average selling price for mattresses. In the second quarter, we began shipping two new mattress products and one redesigned mattress product. We also continued to provide discounted floor models throughout the beginning of the second quarter to two significant new Retail customer accounts that were opened in the first quarter.

Domestic. Domestic Gross profit for the three months ended June 30, 2006 increased to \$63.4 million from \$56.9 million for the same period in 2005, an increase of \$6.5 million, or 11%. The Gross profit margin in our Domestic segment was 44% and 46% for the three months ended June 30, 2006 and June 30, 2005, respectively. For the three months ended June 30, 2006, the Gross profit margin for our Domestic segment was impacted by increases in Retail channel Net sales, new mattress offerings, new account openings and the close out activity of the original design of 'The ClassicBed by Tempur-Pedic™.' Our Domestic cost of sales increased to \$79.3 million for the three months ended June 30, 2006 as compared to \$67.2 million for the three months ended June 30, 2005, an increase of \$12.1 million, or 18%.

International. International Gross profit for the three months ended June 30, 2006 increased to \$43.1 million from \$41.6 million for the same period in 2005, an increase of \$1.5 million, or 4%. The Gross profit margin in our International segment was 56% and 61% for the three months ended June 30, 2006 and June 30, 2005, respectively. For the three months ended June 30, 2006, the Gross profit margin for our International segment was impacted by the continued Retail channel growth, product and geographic mix. Pillow sales have declined in Asia, which negatively impacts the gross margins in this segment of our business. Our International Cost of sales for the three months ended June 30, 2006 increased to \$33.2 million from \$26.9 million for the same period in 2005, an increase of \$6.3 million, or 23%.

[Table of Contents](#)

Selling and marketing expenses. Selling and marketing expenses include advertising and media production associated with our Direct channel; other marketing materials such as catalogs, brochures, videos, product samples, direct customer mailings and point of purchase materials; and sales force compensation and customer service. We also include in Selling and marketing expenses certain new product development costs, including market research and testing for new products. Selling and marketing expenses increased to \$40.3 million for the three months ended June 30, 2006 as compared to \$38.1 million for the three months ended June 30, 2005. Selling and marketing expenses as a percentage of Net sales decreased to 18% during the three months ended June 30, 2006 from 20% for the three months ended June 30, 2005. While total Selling and marketing expenses has decreased as a percentage of Net sales, our advertising spending has remained constant as a percentage of Net sales. This is consistent with our strategy to increase our advertising spending at the same rate as our revenue growth in order to drive growth in our brand awareness.

General and administrative and other expenses. General and administrative and other expenses include management salaries, information technology, professional fees, depreciation of furniture and fixtures, leasehold improvements and computer equipment, expenses for finance, accounting, human resources and other administrative functions, and research and development costs associated with our new product developments. General and administrative and other expenses increased to \$18.9 million for the three months ended June 30, 2006 as compared to \$15.8 million for the three months ended June 30, 2005, an increase of \$3.1 million.

General and administrative and other expenses as a percentage of Net sales were 9% and 8% for the three months ended June 30, 2006 and June 30, 2005, respectively. The increase as a percentage of Net sales was due to increased investment in our information technology infrastructure, professional services, and stock-based compensation expense related to the adoption of SFAS 123R.

Interest expense, net. Interest expense, net, includes the interest costs associated with our borrowings and the amortization of deferred financing costs related to those borrowings. Interest expense, net, increased to \$6.2 million for the three months ended June 30, 2006, as compared to \$4.9 million for the three months ended June 30, 2005, an increase of \$1.3 million, or 27%. This increase in interest expense for the three months ended June 30, 2006 is primarily attributable to higher Long-term debt levels that are directly related to our share repurchase program. We also capitalized interest costs related to the construction of our new manufacturing facility, which offset our increased interest expenses.

Income tax provision. Our Income tax provision includes income taxes associated with taxes currently payable and deferred taxes and includes the impact of net operating losses for certain of our foreign operations. Our effective income tax rates for the six months ended June 30, 2006 and for the six months ended June 30, 2005 differed from the federal statutory rate principally because of certain foreign tax rate differentials, state and local income taxes, valuation allowances on certain net operating losses and the production activities deduction.

Our effective tax rate for the three months ended June 30, 2006 was 36.3%. For the same period in 2005, the effective tax rate was 38.1%. The decrease in the effective tax rate is primarily attributable to a stock-based compensation expense benefit associated with certain options granted prior to the initial public offering and exercised during the second quarter of 2006. In addition, we received a favorable state tax ruling in the fourth quarter of 2005 that reduced our state tax expense.

[Table of Contents](#)

Six Months Ended June 30, 2006 Compared with Six Months Ended June 30, 2005

The following table sets forth Net sales information, by channel, for the periods indicated:

	CONSOLIDATED		DOMESTIC		INTERNATIONAL	
	Six Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005	2006	2005
<i>(Millions)</i>						
Retail	\$ 356.8	\$ 313.0	\$ 242.9	\$ 214.3	\$ 113.9	\$ 98.7
Direct	42.4	54.7	37.6	47.6	4.8	7.1
Healthcare	21.3	23.4	6.0	5.6	15.3	17.8
Third Party	27.1	23.9	7.7	4.5	19.4	19.4
	\$ 447.6	\$ 415.0	\$ 294.2	\$ 272.0	\$ 153.4	\$ 143.0
Domestic	\$ 294.2	\$ 272.0				
International	153.4	143.0				
Total	\$ 447.6	\$ 415.0				

A summary of Net sales by product is below:

	CONSOLIDATED		DOMESTIC		INTERNATIONAL	
	Six Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005	2006	2005
<i>(Millions)</i>						
Net sales:						
Mattresses	\$ 309.8	\$ 284.7	\$ 217.9	\$ 202.0	\$ 91.9	\$ 82.7
Pillows	57.5	62.1	25.8	25.9	31.7	36.2
Other	80.3	68.2	50.5	44.1	29.8	24.1
	\$ 447.6	\$ 415.0	\$ 294.2	\$ 272.0	\$ 153.4	\$ 143.0
Units sold⁽¹⁾:						
Mattresses	373,920	337,156	219,064	198,249	154,856	138,907
Pillows	1,132,947	1,215,518	505,231	510,459	627,716	705,058

⁽¹⁾ Units sold represent Net sales after consideration of returned mattresses and pillows and excludes units shipped to fulfill warranty claims and promotion activities.

Net sales. Net sales for the six months ended June 30, 2006 increased to \$447.6 million from \$415.0 million for the same period in 2005, an increase of \$32.6 million, or 8%. This increase was primarily attributable to an increase in mattress sales in our Retail channel. Mattress sales increased \$25.1 million, or 9%. For the six months ended June 30, 2006, our Retail channel Net sales increased to \$356.8 million from \$313.0 million for the same period in 2005, an increase of \$43.8 million, or 14%.

Our Third Party channel Net sales increased by 13%, which was primarily due to growth in our Canadian and other third party distributors in our Domestic segment. Consolidated pillow sales decreased approximately \$4.6 million from the second quarter of 2005, primarily attributable to a decline in our International sales in Asia to certain Third Party distributors. Our Direct and Healthcare channels' sales declined 22% and 9%, respectively. The Direct channel decline is due primarily to the growth in our Retail channel in the Domestic and International segments which is consistent with our strategy to expand distribution for our products into targeted retail stores. We also decided to focus our International direct model in the U.K. only. The decrease in the Healthcare channel was primarily related to changing healthcare reimbursement practices in certain international markets.

[Table of Contents](#)

Domestic. Domestic Net sales for the six months ended June 30, 2006 increased to \$294.2 million from \$272.0 million for the same period in 2005, an increase of \$22.2 million, or 8%. Our Domestic Retail channel continues to be our largest channel, with \$242.9 million in Net sales for the six months ended June 30, 2006. This is an increase of \$28.6 million, or 13% over the prior year quarter. This increase is due primarily to our efforts to target select retail furniture stores. Our Third Party channel Net sales increased 71% due to continued market share growth in Canada and in certain Central and South American countries. Our Direct channel Net sales decreased 21%. Domestic mattress sales in the second quarter of 2006 increased \$15.9 million, or 8%, over the same period in 2005. In addition, pillow sales had a slight decrease of \$0.1 million.

International. International Net sales for the six months ended June 30, 2006 increased to \$153.4 million from \$143.0 million for the same period in 2005, an increase of \$10.4 million, or 7%. The largest channel in our International segment continues to be our Retail channel, which increased \$15.2 million, or 15%, for the six months ended June 30, 2006. Our Direct channel Net sales decreased 32%, primarily attributable to our decision to focus our International direct model in the U.K. only. Our Third party sales remained relatively flat. In addition, our Healthcare channel Net sales decreased \$2.5 million, or 14%, which was primarily related to changing healthcare reimbursement practices in certain international markets. International mattress sales in the second quarter of 2006 increased \$9.2 million, or 11%, over the second quarter of 2005. Pillow sales for the second quarter of 2006 decreased \$4.5 million, or 12%, as compared to the second quarter of 2005. The decrease in pillow sales is primarily related to our efforts to limit unauthorized sales by third parties into certain existing markets in Asia.

Gross profit. Gross profit for the six months ended June 30, 2006 increased to \$217.8 million from \$212.8 million for the same period in 2005, an increase of \$5.0 million, or 2%. Our margins are impacted by the relative rate of growth in our Retail channel. Sales in our Retail channel are generally at wholesale prices. The overall shift in our product mix to mattresses and other products is also a factor because our mattresses generally carry lower margins than our pillows and are sold with lower margin products such as foundations and bed frames. Increases in raw material costs have impacted our gross margin. However, our ongoing productivity and global sourcing initiatives have mitigated the impact of these cost increases to date. We currently expect our gross margins to improve as a result of these initiatives during the second half of 2006 as compared to the first half of the year.

Our gross margin can also be negatively impacted as a result of opening certain new Retail customer accounts and the rollout of new mattress offerings. We provide discounted floor models to certain new Retail customers and on new mattresses, which can temporarily reduce our average selling price for mattresses. During the six months ended June 30, 2006, we opened two significant new Retail customer accounts to whom we provided these discounted floor models and began shipping new mattress offerings.

Domestic. Domestic Gross profit for the six months ended June 30, 2006 increased to \$130.2 million from \$126.9 million for the same period in 2005, an increase of \$3.3 million, or 3%. The Gross profit margin in our Domestic segment was 44% and 47% for the six months ended June 30, 2006 and June 30, 2005, respectively. For the six months ended June 30, 2006, the Gross profit margin for our Domestic segment was impacted by increases in Retail channel Net sales, new mattress offerings, new account openings and the close out activity of the original design of 'The ClassicBed by Tempur-Pedic™.' Our Domestic cost of sales increased to \$164.0 million for the six months ended June 30, 2006 as compared to \$145.1 million for the six months ended June 30, 2005, an increase of \$18.9 million, or 13%.

International. International Gross profit for the six months ended June 30, 2006 increased to \$87.6 million from \$85.9 million for the same period in 2005, an increase of \$1.7 million, or 2%. The Gross profit margin in our International segment was 57% and 60% for the six months ended June 30, 2006 and June 30, 2005, respectively. For the six months ended June 30, 2006, the Gross profit margin for our International segment was impacted by the continued Retail channel growth, product, and geographic mix. Pillow sales have declined in Asia which negatively impacts the gross margins in the International segments. Our International Cost of sales for the six months ended June 30, 2006 increased to \$65.8 million from \$57.1 million for the same period in 2005, an increase of \$8.7 million, or 15%.

[Table of Contents](#)

Selling and marketing expenses. Selling and marketing expenses increased to \$85.1 million for the six months ended June 30, 2006 as compared to \$83.1 million for the six months ended June 30, 2005. Selling and marketing expenses as a percentage of Net sales decreased to 19% for the six months ended June 30, 2006 from 20% for the same period for 2005. While total Selling and marketing expenses has decreased as a percentage of Net sales, our advertising spending has remained constant as a percentage of Net sales. This is consistent with our strategy to increase our advertising spending at the same rate as our revenue growth in order to drive growth in our brand awareness.

General and administrative and other expenses. General and administrative and other expenses increased to \$38.2 million for the six months ended June 30, 2006 as compared to \$35.7 million for the six months ended June 30, 2005, an increase of \$2.5 million. The increase was primarily attributable to increased investment in our information technology infrastructure, professional services, and share based compensation expense related to the adoption of SFAS 123R.

General and administrative and other expenses as a percentage of Net sales remained relatively flat for the six months ended June 30, 2006 compared to the same period in 2005.

Interest expense, net. Interest expense, net, increased to \$10.7 million for the six months ended June 30, 2006, as compared to \$10.2 million for the six months ended June 30, 2005, an increase of \$0.5 million, or 5%. This increase in interest expense for the six months ended June 30, 2006 is primarily attributable to higher Long-term debt levels that are directly related to our share repurchase program. We also capitalized interest costs related to the construction of our new manufacturing facility, which offset our increased interest expenses.

Income tax provision. Our effective income tax rates for the six months ended June 30, 2006 and 2005 differed from the federal statutory rate principally because of certain foreign tax rate differentials, state and local income taxes, valuation allowances on certain net operating losses, compensation expense associated with certain options granted prior to the initial public offering, and the production activities deduction.

Our effective tax rate for the six months ended June 30, 2006 was 36.6%. For the same period in 2005, the effective tax rate was 38.1%. The decrease in the effective tax rate is primarily attributable to a compensation expense benefit associated with certain options granted prior to the initial public offering and exercised during the second quarter of 2006. In addition, we received a favorable state tax ruling in the fourth quarter of 2005 that reduced our state tax expense.

Liquidity and Capital Resources

Liquidity

Our principal sources of funds are cash flows from operations and borrowings. Our principal uses of funds consist of capital expenditures, payments of principal and interest on our debt facilities, and share repurchases made from time to time pursuant to a share repurchase program. At June 30, 2006, we had working capital of \$94.7 million including Cash and cash equivalents of \$15.8 million as compared to working capital of \$107.3 million including \$17.9 million in Cash and cash equivalents as of December 31, 2005. Increased Accounts payable, Income taxes payable and Accrued expenses, coupled with decreases in inventory and cash, led to a 12% decrease in working capital from December 31, 2005 to June 30, 2006.

Our cash flow from operations increased to \$86.5 million for the six months ended June 30, 2006 as compared to \$49.1 million for the six months ended June 30, 2005. The increase in operating cash flow was primarily related to our efforts to improve our cash cycle. Decreases in our inventory levels provided operating cash flows of \$29.0 million for the six months ended June 30, 2006 as compared to the same period in 2005. Changes in the remaining operating assets and liabilities provided additional operating cash flow of \$9.3 million, primarily increases in Accounts payable and Accrued expenses.

[Table of Contents](#)

Net cash used in investing activities decreased to \$19.0 million for the six months ended June 30, 2006 as compared to \$49.7 million for the six months ended June 30, 2005, a decrease of \$30.7 million. Investing activities in the six months ended June 30, 2006 consisted primarily of \$13.0 million related to the construction of our new manufacturing facility in New Mexico, as compared to \$42.5 million in construction costs for the six months ended June 30, 2005.

Cash flow used by financing activities was \$71.0 million for the six months ended June 30, 2006 as compared to cash flow provided by financing activities of \$5.4 million for the six months ended June 30, 2005, representing an increase in cash flow used of \$76.4 million. This increase is due primarily to our share repurchases of \$144.0 million, which were offset by an increase of \$67.6 million in net associated borrowings on our 2005 Senior Credit facilities.

Capital Expenditures

Capital expenditures totaled \$18.6 million for the six months ended June 30, 2006 including \$2.5 million in capitalized interest costs related to the construction of our new manufacturing facility in New Mexico. Capital expenditures totaled \$48.7 million for the six months ended June 30, 2005. We currently expect our 2006 capital expenditures to be approximately \$38.0 million, including approximately \$19.5 million for the completion of the new manufacturing facility. For the remainder of 2006, we expect our capital expenditures to be approximately \$19.4 million. As of June 30, 2006 we had commitments of \$2.9 million associated with the construction of our new plant.

In order to meet anticipated future demands for our products, we commenced construction of our third manufacturing facility in September 2004, located in Albuquerque, New Mexico. The new facility is expected to be completed in the fourth quarter of 2006. Our expected capital expenditures related to this facility are approximately \$90.0 million plus capitalized interest. This facility will allow us to meet the demands for our products primarily in the western U.S. as well as certain third party distributors.

Debt Service

Our total long-term debt increased to \$394.5 million as of June 30, 2006 from \$313.7 million as of December 31, 2005. On June 30, 2006, we made a voluntary prepayment of \$20.5 million on our Foreign Term Loan, in excess of the scheduled principal payment of \$4.9 million, for a total principal reduction of \$25.4 million. This was the Company's second voluntary prepayment since December 31, 2005. On March 31, 2006, we made a prepayment of \$21.8 million, in excess of the scheduled principal payment of \$5.8 million. For the six months ended June 30, 2006 we have made voluntary prepayments totaling \$42.3 million, which coupled with scheduled principal payments has lowered our European term loan by approximately \$53.0 million. These prepayments were funded entirely from the operating cash flows in our International segment. Additionally, during the six months ended June 30, 2006, we increased borrowings on our domestic revolving credit facility by \$120.5 million in order to fund our share repurchase program, through which we purchased 11.3 million shares at a total cost of \$144.0 million.

See Note 4 in the Notes to Condensed Consolidated Financial Statements in ITEM 1 for a discussion of our long-term debt.

Stockholders' Equity

On October 18, 2005, our Board of Directors authorized the repurchase of up to \$80.0 million of common stock. Share repurchases under this program may be made through open market transactions, negotiated purchases or otherwise, at times and in such amounts as we deemed appropriate. During 2005, we repurchased 6.8 million shares, at a total cost of \$76.0 million. We funded these share repurchases from borrowings under the 2005 Senior Credit Facility and funds from operations.

[Table of Contents](#)

On January 25, 2006, our Board of Directors amended the share repurchase program described above to increase the total authorization by an additional \$100.0 million. On May 22, 2006, our Board of Directors further amended the share repurchase program to increase the total authorization under the share repurchase program by an additional \$40.0 million for a total authorization to purchase up to \$220.0 million of Tempur-Pedic International's common stock. During the six months ended June 30, 2006, we repurchased 11.3 million shares at a total cost of \$144.0 million. As of June 30, 2006, the Company had completed its existing share repurchase authorization. The share repurchases were funded from borrowings under the 2005 Senior Credit Facility and funds from operations.

Factors That May Affect Future Performance

Managing Growth—We have grown rapidly, with our Net sales increasing from \$221.5 million in 2001 to \$836.7 million for 2005 and \$447.6 million for the six months ended June 30, 2006. Our growth has placed, and will continue to place, a strain on our management, production, product distribution network, information systems and other resources. In response to these challenges, management has continued to invest in increased production capacity, enhanced operating and financial infrastructure and systems and continued expansion of the human resources in our operations. Our expenditures for advertising and other marketing-related activities are made as advertising rates are favorable to us and as the continued growth in the business allows us the ability to invest in building our brand.

Competition—Participants in the mattress and pillow industries compete primarily on price, quality, brand name recognition, product availability and product performance. We compete with a number of different types of mattress alternatives, including standard innerspring mattresses, other foam mattresses, waterbeds, futons, air beds and other air-supported mattresses. These alternative products are sold through a variety of channels, including furniture stores, specialty bedding stores, department stores, mass merchants, wholesale clubs, telemarketing programs, television infomercials and catalogs.

Our largest competitors have significant financial, marketing and manufacturing resources and strong brand name recognition, and sell their products through broad and well established distribution channels. Additionally, we believe that a number of our significant competitors offer mattress products claimed to be similar to our TEMPUR® mattresses and pillows. We are susceptible to competition from lower priced product offerings. We provide strong channel profits to our retailers and distributors which management believes will continue to provide an attractive business model for our retailers and discourage them from carrying competing lower-priced products.

Significant Growth Opportunities—We believe there are significant opportunities to take market share from the innerspring mattress industry as well as other sleep surfaces. Our market share of the overall mattress industry is relatively small in terms of both dollars and units, which we believe provides us with a significant opportunity for growth. By expanding our brand awareness and offering superior sleep surfaces, we believe consumers will continue to adopt our products at an increasing rate, which should expand our market share. We believe that the premium and specialty bedding categories which we target will continue to grow at a faster rate than the overall mattress industry and we believe we will continue to experience the benefits of this consumer adoption.

In addition, by expanding distribution within our existing accounts, we believe we have the opportunity to grow our business. We believe that by extending our product line, we should be able to continue to expand the number of Tempur-Pedic models offered at the retail store level, which should lead to increased sales.

Expanding distribution into new stores is also a source of growth opportunities. Our products are currently sold in approximately 5,760 furniture and bedding retail stores in the U. S., out of a total of approximately 10,000 stores we have identified as appropriate targets. Within this addressable market of approximately 10,000 stores, our plan is to increase our total penetration to a total of 7,000 to 8,000 stores over time. Our products are also

[Table of Contents](#)

sold in approximately 4,340 furniture retail and department stores outside the U.S., out of a total of approximately 7,000 stores that we have identified as appropriate targets. For the three months ended June 30, 2006, we added a net of approximately 160 stores in the U.S. and approximately 90 stores internationally to our Retail channel. For the six months ended June 30, 2006 we added a net of approximately 450 stores in the U.S. and approximately 290 stores internationally to our Retail channel. In addition, we have a significant installed pillow base in our Asia market that we believe creates an opportunity to develop a successful mattress market. We are continuing to develop products that are responsive to consumer demand in our markets.

In addition to these growth opportunities, we have only a small percentage market share in the nursing home and hospital markets. Clinical evidence indicates that our products are both effective and cost efficient for the prevention and treatment of pressure ulcers, or bed sores, a major problem for elderly and bed-ridden patients. We have recently begun partnering with healthcare vendors in an indirect sales method whereby the vendor integrates our product into their products, in order to improve patient comfort and wellness.

We are also focused on the hospitality industry, and have recently devoted increased resources to this important area. We believe there are growth opportunities for our products through this channel as well as the opportunity to increase consumer trial and brand awareness.

Financial Leverage—As of June 30, 2006, we had \$394.5 million of Long-term debt outstanding, and our Stockholders' Equity was \$146.2 million. Higher financial leverage makes us more vulnerable to general adverse, competitive, economic and industry conditions. We believe that operating margins combined with the inherent operating leverage in the business will enable us to de-leverage the business in a manner consistent with historical experience. There can be no assurance, however, that our business will generate sufficient cash flow from operations or that future borrowing will be available under our 2005 Senior Credit Facility or otherwise, to enable us to de-leverage the business.

Exchange Rates—As a multinational company, we conduct our business in a wide variety of currencies and are therefore subject to market risk for changes in foreign exchange rates. We use foreign exchange forward contracts to manage a portion of the exposure to the risk of the eventual net cash inflows and outflows resulting from foreign currency denominated transactions between Tempur-Pedic subsidiaries and their customers and suppliers, as well as between the Tempur-Pedic subsidiaries themselves. These hedging transactions may not succeed in managing our foreign currency exchange rate risk. See "ITEM 3. Quantitative and Qualitative Disclosures About Market Risk—Foreign Currency Exposures" under Part I of this report.

Foreign currency exchange rate movements also create a degree of risk by affecting the U.S. dollar value of sales made and costs incurred in foreign currencies. We do not enter into hedging transactions to hedge this risk. Consequently, our reported earnings and financial position could fluctuate materially as a result of foreign exchange gains or losses. Our outlook assumes no significant changes in currency values from current rates. Should currency rates change sharply, our results could be negatively impacted. See "ITEM 3. Quantitative and Qualitative Disclosures About Market Risk—Foreign Currency Exposures" under Part I of this report.

Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see "ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K for the year ended December 31, 2005. There have been no material changes to our critical accounting policies and estimates in 2006, except as follows:

Stock-Based Compensation—In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS 123 (revised 2004), "Share-Based Payment" (SFAS 123R), which is a revision of SFAS 123, "Accounting for Stock Based Compensation" (SFAS 123). SFAS 123R requires all share-based payments to employees,

[Table of Contents](#)

including grants of employee stock options, to be recognized in the financial statements based on their fair values. Pro forma disclosure is no longer an alternative to financial statement recognition. SFAS 123R became effective for annual periods beginning after June 15, 2005.

SFAS 123R permits public companies to adopt its requirements using one of two methods. The first adoption method is a “modified prospective” approach in which compensation cost is recognized beginning with the effective date (i) based on the requirements of SFAS 123R for all share-based payments granted after the effective date and (ii) based on the requirements of SFAS 123 for all share-based payments granted to employees prior to the effective date of SFAS 123R that remain unvested on the effective date. The second adoption method is a “modified retrospective” approach, which includes the requirements of the modified prospective method described above, but also permits entities to restate, based on the amounts previously recognized under SFAS 123 for purposes of pro forma disclosures, either (i) all prior periods presented or (ii) prior interim periods in the year of adoption.

We adopted SFAS 123R on January 1, 2006 using the modified prospective method for the transition and expect to recognize approximately \$2.2 million, pre-tax, in additional expense in 2006 based on option grants outstanding as of December 31, 2005. The impact of adoption of SFAS 123R on future grants cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. Additionally, we have continued to use the Black-Scholes option pricing model to calculate the fair value of share based payments under SFAS 123R. Compensation amounts so determined will be expensed over the applicable estimated life. See Note 6 in the Notes to Condensed Consolidated Financial Statements in ITEM 1 for further discussion of our adoption of SFAS 123R.

Impact of Recently Issued Accounting Pronouncements

See Note 2 in the Notes to Condensed Consolidated Financial Statements in ITEM 1 for a full description of recent accounting pronouncements, including the expected dates of adoption and estimated effects on results of operations and financial condition, which is incorporated herein by reference.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Exposures

Our earnings, as a result of our global operating and financing activities, are exposed to changes in foreign currency exchange rates, which may adversely affect our results of operations and financial position. Our current outlook assumes no significant changes in currency values from current rates. Should currency rates change sharply, our results could be negatively impacted.

We protect a portion of our currency exchange exposure with foreign currency forward contracts. A sensitivity analysis indicates the potential loss in fair value on foreign currency forward contracts outstanding at June 30, 2006, resulting from a hypothetical 10% adverse change in all foreign currency exchange rates against the U.S. Dollar, is approximately \$0.4 million. Such losses would be largely offset by gains from the revaluation or settlement of the underlying assets and liabilities that are being protected by the foreign currency forward contracts.

We do not apply hedge accounting to the foreign currency forward contracts used to offset currency-related changes in the fair value of foreign currency denominated assets and liabilities. These contracts are marked-to-market through earnings at the same time that the exposed assets and liabilities are remeasured through earnings.

Interest Rate Risk

We are exposed to changes in interest rates. Our 2005 Senior Credit Facility and the Series A bonds issued in connection with our New Mexico facility are variable-rate debt. We currently do not expect our debt levels under the 2005 Senior Credit Facility to have a materially different impact on our interest rate risk from that associated with our prior senior credit facility.

Interest rate changes generally do not affect the market value of such debt but do impact the amount of our interest payments and therefore, our future earnings and cash flows, assuming other factors are held constant. On June 30, 2006, we had variable-rate debt of approximately \$318.2 million. Holding other variables constant, including levels of indebtedness, a one hundred basis point increase in interest rates on our variable-rate debt would cause an estimated reduction in income before income taxes for the next year of approximately \$3.2 million.

In January 2003, the Company paid premiums to purchase two three-year interest rate caps for the purpose of protecting cash flows associated with interest payments on \$60.0 million of the existing variable-rate debt outstanding, at any given time, against LIBOR rates rising above 5%. The interest rate caps expired on March 31, 2006 and were not renewed.

ITEM 4. CONTROLS AND PROCEDURES

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), as of the end of the period covered by this report. Based on that evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of June 30, 2006 and designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.

During our last fiscal quarter, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II
OTHER INFORMATION**

ITEM 1. LEGAL PROCEEDINGS

Between October 7, 2005 and November 21, 2005, five complaints were filed against Tempur-Pedic International and certain of its directors and officers in the United States District Court for the Eastern District of Kentucky (Lexington Division) purportedly on behalf of a class of shareholders who purchased the Company's stock between April 22, 2005 and September 19, 2005. On December 29, 2005, the court consolidated these five actions (the Securities Law Action). Lead plaintiffs filed a consolidated complaint on February 27, 2006. In their consolidated complaint, lead plaintiffs assert claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Lead plaintiffs allege that certain of Tempur-Pedic International's public disclosures regarding its financial performance between April 22, 2005 and September 19, 2005 were false and/or misleading. The principal allegation set forth in the Securities Law Action is that Tempur-Pedic International did not disclose the impact of competition on its prospects. The plaintiffs seek compensatory damages, costs, fees and other relief within the Court's discretion. On June 14, 2006, Tempur-Pedic International filed a motion to dismiss all claims in the Securities Law Action. That motion is currently pending before the Court. We strongly believe that the Securities Law Action lacks merit, and we intend to defend against the claims vigorously. However, due to the inherent uncertainties of litigation, we cannot predict the outcome of the Securities Law Action at this time, and we can give no assurance that these claims will not have a material adverse affect on our financial position or results of operations.

On November 10, 2005 and December 15, 2005, complaints were filed in the state courts of Delaware and Kentucky, respectively, against certain officers and directors of Tempur-Pedic International, purportedly derivatively on behalf of the Company (the Derivative Complaints). The Derivative Complaints assert that the named officers and directors breached their fiduciary duties when they allegedly sold Tempur-Pedic International's securities on the basis of material non-public information in 2005. The Delaware Derivative Complaint also asserts a claim for breach of fiduciary duty with respect to the disclosures that also are the subject of the Securities Law Action described above. On December 14, 2005 and January 26, 2006, respectively, the Delaware court and Kentucky court stayed these derivative actions pending the outcome of the motion to dismiss that defendants have filed in the Securities Law Action. Tempur-Pedic International is also named as a nominal defendant in the Derivative Complaints, although the actions are derivative in nature and purportedly asserted on behalf of Tempur-Pedic International. Tempur-Pedic International is in the process of evaluating these claims.

We are involved in various other legal proceedings incident to the ordinary course of our business. We believe that the outcome of all such pending legal proceedings in the aggregate will not have a materially adverse effect on our business, financial condition, liquidity, or operating results.

ITEM 1A. RISK FACTORS

The following risk factors and other information included in this report should be carefully considered. Please also see "Special Note Regarding Forward-Looking Statements" on page 3.

We operate in the highly competitive mattress and pillow industries, and if we are unable to compete successfully, we may lose customers and our sales may decline.

Participants in the mattress and pillow industries compete primarily on price, quality, brand name recognition, product availability and product performance. Our premium mattresses compete with a number of different types of mattress alternatives, including standard innerspring mattresses, viscoelastic mattresses, foam mattresses, waterbeds, futons, air beds and other air-supported mattresses. These alternative products are sold through a variety of channels, including furniture stores, specialty bedding stores, department stores, mass merchants, wholesale clubs, telemarketing programs, television infomercials and catalogs.

Our largest competitors have significant financial, marketing and manufacturing resources and strong brand name recognition, and sell their products through broad and well established distribution channels. Additionally,

[Table of Contents](#)

we believe that a number of our significant competitors now offer mattress products claimed to be similar to our viscoelastic mattresses and pillows. These competitors or other mattress manufacturers may aggressively pursue the viscoelastic mattress market. Any such competition by established manufacturers or new entrants into the market could have a material, adverse effect on our business, financial condition and operating results by causing our products to lose market share. In addition, should any of our competitors reduce prices on premium mattress products, we may be required to implement price reductions in order to remain competitive, which could significantly impair our liquidity and profitability. The pillow industry is characterized by a large number of competitors, none of which is dominant, but many of which have greater resources than us and greater brand recognition than our brand.

We may be unable to sustain our profitability, which could impair our ability to service our indebtedness and make investments in our business.

Our ability to service our indebtedness depends on our ability to maintain our profitability. Our sales growth slowed in 2005, with Net sales growing at a 22% rate from 2004, as compared to a sales growth rate of 43% for 2004 compared to 2003. Net sales for the first six months of 2006 grew at an 8% rate compared to the first half of 2005. We may not be able to maintain our profitability on a quarterly or annual basis in future periods. Further, our profitability will depend upon a number of factors, including without limitation:

- the level of competition in the mattress and pillow industry;
- our ability to continue to successfully execute our strategic initiatives;
- our ability to effectively sell our products through our distribution channels in volumes sufficient to drive growth and leverage our cost structure and advertising spending;
- our ability to continuously improve our products to offer new and enhanced consumer benefits, better quality and reduced costs;
- our ability to maintain efficient, timely and cost-effective production and utilization of our manufacturing capacity;
- the efficiency and effectiveness of our advertising campaigns and other marketing programs in building product and brand awareness, driving traffic to our distribution channels and increasing sales;
- our ability to successfully identify and respond to emerging trends in the mattress and pillow industry;
- our ability to maintain public association of our brand with premium products, including overcoming any impact on our brand caused by some of our customers seeking to sell our products at a discount to our recommended price;
- the level of consumer acceptance of our products; and
- general economic conditions and consumer confidence.

Our operating results are increasingly subject to fluctuations, which could adversely affect the market price of our common stock.

A significant portion of our growth in Net sales is attributable to growth in sales in our Domestic retail channel, particularly sales to furniture stores. We believe that our sales of mattresses and pillows to furniture stores are subject to seasonality inherent in the bedding industry with sales expected to be generally lower in the second and fourth quarters and higher in the first and third quarters. Accordingly, our Net sales may be affected by this seasonality as our domestic retail sales channel continues to grow as a percentage of our overall Net sales.

In addition, to seasonal fluctuations, the demand for our premium products can fluctuate significantly based on a number of other factors including general economic conditions and consumer confidence, and the timing of price increases announced by us or our competitors. We believe that as our consumer base continues to expand the average demographics of our consumer base change, with a greater percentage of middle income consumers. This change in our consumer base makes our business more susceptible to general economic factors that impact disposable income or consumer confidence.

Our advertising expenditures may not result in increased sales or generate the levels of product and brand name awareness we desire and we may not be able to manage our advertising expenditures on a cost-effective basis.

A significant component of our marketing strategy involves the use of direct marketing to generate sales. Future growth and profitability will depend in part on the effectiveness and efficiency of our advertising expenditures, including our ability to:

- create greater awareness of our products and brand name;
- determine the appropriate creative message and media mix for future advertising expenditures;
- effectively manage advertising costs, including creative and media, to maintain acceptable costs per inquiry, costs per order and operating margins; and
- convert inquiries into actual orders.

We are subject to fluctuations in the cost of raw materials, and increases in these costs would reduce our liquidity and profitability.

The major raw materials that we purchase for production are chemicals and proprietary additives. The price and availability of these raw materials are subject to market conditions affecting supply and demand, and prices have risen substantially on certain materials since August 2005. Our financial condition and results of operations may be materially and adversely affected by increases in raw material costs to the extent we are unable to pass those higher costs to our customers. For additional discussion, see also “Part I, ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Loss of suppliers and disruptions in the supply of our raw materials could increase our costs of production and reduce our ability to compete effectively.

We currently obtain the raw materials used to produce our pressure-relieving TEMPUR® material from outside sources. We currently acquire chemicals and proprietary additives from a number of suppliers with manufacturing locations around the world. If we were unable to obtain chemicals and proprietary additives from these suppliers, we would have to find replacement suppliers. Any substitute arrangements for chemicals and proprietary additives might not be on terms as favorable to us. We maintain relatively small supplies of our raw materials on-site, and any disruption in the on-going shipment of supplies to us could interrupt production of our products, which could result in a decrease of our sales, or could cause an increase in our cost of sales, and either of these results could decrease our liquidity and profitability. In addition, we continue to outsource the procurement of certain goods and services from suppliers in foreign countries. If we were no longer able to outsource these suppliers, we could source it elsewhere at a higher cost. To the extent we are unable to pass those higher costs to our customers, these costs could reduce our gross profit margin, which could result in a decrease in our liquidity and profitability.

We may face exposure to product liability, which could reduce our liquidity and profitability and reduce consumer confidence in our products.

We face an inherent business risk of exposure to product liability claims if the use of any of our products results in personal injury or property damage. In the event that any of our products prove to be defective, we may be required to recall or redesign those products. We maintain insurance against product liability claims, but such coverage may not continue to be available on terms acceptable to us or be adequate for liabilities actually incurred. A successful claim brought against us in excess of available insurance coverage could impair our liquidity and profitability, and any claim or product recall that results in significant adverse publicity against us, could result in consumers purchasing fewer of our products, which would also impair our liquidity and profitability.

We may be adversely affected by fluctuations in exchange rates, which could affect our results of operations, the costs of our products and our ability to sell our products in foreign markets.

Approximately 35% and 34% of our Net sales were denominated in foreign currency for the three and six months ended June 30, 2006, respectively. As a multinational company, we conduct our business in a wide variety of currencies and are therefore subject to market risk for changes in foreign exchange rates. We use foreign exchange forward contracts to manage a portion of the exposure to the risk of the eventual net cash inflows and outflows resulting from foreign currency denominated transactions between Tempur-Pedic subsidiaries and their customers and suppliers, as well as between Tempur-Pedic subsidiaries themselves from time to time. The hedging transactions may not succeed in managing our foreign currency exchange rate risk. See “ITEM 3. Quantitative and Qualitative Disclosures About Market Risk—Foreign Currency Exposures” under Part I of this report.

Foreign currency exchange rate movements also create a degree of risk by affecting the U.S. dollar value of sales made and costs incurred in foreign currencies. We do not enter into hedging transactions to hedge this risk. Consequently, our reported earnings and financial position could fluctuate materially as a result of foreign exchange gains or losses. Our outlook assumes no significant changes in currency values from current rates. Should currency rates change sharply, our results could be negatively impacted. See “ITEM 3 Quantitative and Qualitative Disclosures About Market Risk—Foreign Currency Exposures” under Part I of this report.

Regulatory requirements may require costly expenditures and expose us to liability.

Our products and our marketing and advertising programs are and will continue to be subject to regulation in the U.S. by various federal, state and local regulatory authorities, including the Federal Trade Commission and the U.S. Food and Drug Administration. In addition, other governments and agencies in other jurisdictions regulate the sale and distribution of our products. Compliance with these regulations may have an adverse effect on our business. For example, compliance with changes in fire resistance laws may be costly and could have an adverse impact on the performance of our products. In February 2006, the U.S. Consumer Product Safety Commission issued new rules relating to fire retardancy standards for the mattress and pillow industry. The State of California adopted new fire retardancy standards beginning in 2005. We have developed product modifications that allow us to meet these new standards. Required product modifications have added cost to our products. Many foreign jurisdictions also regulate fire retardancy standards, and changes to these standards and changes in our products that require compliance with additional standards would raise similar risks.

Our marketing and advertising practices could also become the subject of proceedings before regulatory authorities or the subject of claims by other parties. In addition, we are subject to federal, state and local laws and regulations relating to pollution, environmental protection and occupational health and safety. We may not be in complete compliance with all such requirements at all times. We have made and will continue to make capital and other expenditures to comply with environmental and health and safety requirements. If a release of hazardous substances occurs on or from our properties or any associated offsite disposal location, or if contamination from prior activities is discovered at any of our properties, we may be held liable and the amount of such liability could be material.

An increase in our product return rates or an inadequacy in our warranty reserves could reduce our liquidity and profitability.

Part of our Domestic marketing and advertising strategy in certain Domestic channels focuses on providing up to a 120-day money back guarantee under which customers may return their mattress and obtain a refund of the purchase price. For the three and six months ended June 30, 2006, in the U.S. we had approximately \$7.9 million and \$17.5 million in returns, respectively for a return rate of approximately 6% of our Net sales in the U.S. for both periods. As we expand our sales, our return rates may not remain within our historical levels. An increase in return rates could significantly impair our liquidity and profitability. We also currently provide our customers with a limited, pro-rata 20-year warranty on mattresses sold in the U.S. and a limited 15-year warranty on

[Table of Contents](#)

mattresses sold outside of the U.S. However, as we have only been selling mattresses in significant quantities since 1992, and have released new products in recent years, many are fairly early in their product life cycles. We also provide 2-year to 3-year warranties on pillows.

Because our products have not been in use by our customers for the full warranty period, we rely on the combination of historical experience and product testing for the development of our estimate for warranty claims. However, our actual level of warranty claims could prove to be greater than the level of warranty claims we estimated based on our products' performance during product testing. If our warranty reserves are not adequate to cover future warranty claims, their inadequacy could have a material adverse effect on our liquidity and profitability.

We are subject to risks from our international operations, such as increased costs and the potential absence of intellectual property protection, which could impair our ability to compete and our profitability.

We currently conduct international operations in 14 countries directly and in approximately 60 additional countries through distributors, and we may pursue additional international opportunities. We generated approximately 65% and 66% of our Net sales from non-U.S. operations during the three and six months ended June 30, 2006, and international suppliers provided a significant portion of our manufacturing material during this period. Our international operations are subject to the customary risks of operating in an international environment, including complying with foreign laws and regulations and the potential imposition of trade or foreign exchange restrictions, tariff and other tax increases, fluctuations in exchange rates, inflation and unstable political situations, the potential unavailability of intellectual property protection and labor issues.

If we are not able to protect our trade secrets or maintain our trademarks, patents and other intellectual property, we may not be able to prevent competitors from developing similar products or from marketing in a manner that capitalizes on our trademarks, and this loss of a competitive advantage could decrease our profitability and liquidity.

We rely on trade secrets to protect the design, technology and function of our TEMPUR® material and our products. To date, we have not sought U.S. or international patent protection for our principal product formula and manufacturing processes. Accordingly, we may not be able to prevent others from developing viscoelastic material and products that are similar to or competitive with our products. Our ability to compete effectively with other companies also depends, to a significant extent, on our ability to maintain the proprietary nature of our owned and licensed intellectual property. We own several patents on aspects of our products and have patent applications pending on aspects of our manufacturing processes. However, the principal product formula and manufacturing processes for our TEMPUR® material and our products are not patented and we must maintain these as trade secrets in order to protect this intellectual property. We own 12 U.S. patents, and we have 16 U.S. patent applications pending. Further, we own 46 foreign patents, and we have 31 foreign patent applications pending. In addition, we hold approximately 240 trademark registrations worldwide. We own U.S. and foreign registered trade names and service marks and have applications for the registration of trade names and service marks pending domestically and abroad. We also license certain intellectual property rights from third parties.

Although our trademarks are currently registered in the U.S. and registered or pending in 59 foreign countries, they could be circumvented, or violate the proprietary rights of others, or we could be prevented from using them if challenged. A challenge to our use of our trademarks could result in a negative ruling regarding our use of our trademarks, their validity or their enforceability, or could prove expensive and time consuming in terms of legal costs and time spent defending against it. Any loss of trademark protection could result in a decrease in sales or cause us to spend additional amounts on marketing, either of which could decrease our liquidity and profitability. In addition, if we incur significant costs defending our trademarks that could also decrease our liquidity and profitability. In addition, we may not have the financial resources necessary to enforce or defend our trademarks. Furthermore, our patents may not provide meaningful protection and patents may never be issued for our pending patent applications. It is also possible that others could bring claims of

[Table of Contents](#)

infringement against us, as our principal product formula and manufacturing processes are not patented, and that any licenses protecting our intellectual property could be terminated. If we were unable to maintain the proprietary nature of our intellectual property and our significant current or proposed products, this loss of a competitive advantage could result in decreased sales or increased operating costs, either of which would decrease our liquidity and profitability.

In addition, the laws of certain foreign countries may not protect our intellectual property rights and confidential information to the same extent as the laws of the U.S. or the European Union. Third parties, including competitors, may assert intellectual property infringement or invalidity claims against us that could be upheld. Intellectual property litigation, which could result in substantial cost to and diversion of effort by us, may be necessary to protect our trade secrets or proprietary technology or for us to defend against claimed infringement of the rights of others and to determine the scope and validity of others' proprietary rights. We may not prevail in any such litigation, and if we are unsuccessful, we may not be able to obtain any necessary licenses on reasonable terms or at all.

Because we depend on our significant customers, a decrease or interruption in their business with us would reduce our sales and profitability.

Our top five customers, collectively, accounted for 16% and 13% of our Net sales for the three and six months ended June 30, 2006, respectively. Many of our customer arrangements are by purchase order or are terminable at will at the option of either party. A substantial decrease or interruption in business from our significant customers could result in write-offs or in the loss of future business and could reduce our liquidity and profitability.

In the future, retailers may consolidate, undergo restructurings or reorganizations, or realign their affiliations, any of which could decrease the number of stores that carry our products or increase the ownership concentration in the retail industry. Some of these retailers may decide to carry only a limited number of brands of mattress products, which could affect our ability to sell our products to them on favorable terms, if at all. Our loss of significant customers would impair our sales and profitability and have a material adverse effect on our business, financial condition and results of operations.

We produce all of our products in two manufacturing facilities and have commenced construction on a third manufacturing facility, and unexpected equipment failures, delays in deliveries, catastrophic loss or construction delays may lead to production curtailments or shutdowns.

We manufacture all of our products at our two facilities in Aarup, Denmark and Duffield, Virginia and are in the process of constructing a third facility in Albuquerque, New Mexico. An interruption in production capabilities at these plants as a result of equipment failure could result in our inability to produce our products, which would reduce our sales and earnings for the affected period. In addition, we generally deliver our products only after receiving the order from the customer or the retailer and thus do not hold large inventories. In the event of a stoppage in production at either of our manufacturing facilities, even if only temporary, or if we experience delays as a result of events that are beyond our control, delivery times could be severely affected. For example, our third party carrier could potentially be unable to deliver our products within acceptable time periods due to a labor strike or other disturbance in its business. Any significant delay in deliveries to our customers could lead to increased returns or cancellations and cause us to lose future sales. Any increase in freight charges could increase our costs of doing business and harm our profitability. We have introduced new distribution programs to increase our ability to deliver products on a timely basis, but if we fail to deliver products on a timely basis, we may lose sales which could decrease our liquidity and profitability. Our manufacturing facilities are also subject to the risk of catastrophic loss due to unanticipated events such as fires, explosions or violent weather conditions. We may in the future experience material plant shutdowns or periods of reduced production as a result of equipment failure, delays in deliveries or catastrophic loss.

A deterioration in labor relations could disrupt our business operations and increase our costs, which could decrease our liquidity and profitability.

As of June 30, 2006, we had approximately 1,300 full-time employees, with approximately 600 in the U.S., 300 in Denmark and 400 in the rest of the world. The employees in Denmark are under a government labor union contract, but those in the U.S. are not. Any significant increase in our labor costs could decrease our liquidity and profitability and any deterioration of employee relations, slowdowns or work stoppages at any of our locations, whether due to union activities, employee turnover or otherwise, could result in a decrease in our Net sales or an increase in our costs, either of which could decrease our liquidity and profitability.

The loss of the services of any members of our senior management team could impair our ability to execute our business strategy and as a result, reduce our sales and profitability.

We depend on the continued services of our senior management team. The loss of key personnel could have a material adverse effect on our ability to execute our business strategy and on our financial condition and results of operations. We do not maintain key-person insurance for members of our senior management team.

Our leverage limits our flexibility and increases our risk of default.

As of June 30, 2006, we had \$394.5 million in total Long-term debt outstanding. In addition, as of June 30, 2006, our Stockholders' Equity was \$146.2 million. Between October 2005 and June 30, 2006 we have repurchased a total of \$220.0 million in common stock pursuant to a stock repurchase program authorized by our Board of Directors in the total amount of \$220.0 million. We funded the repurchase in part through borrowings under our 2005 Senior Credit Facility, which has substantially increased our leverage. Our Board of Directors may authorize additional share repurchases in the future and we may fund these repurchases with debt. Our degree of leverage could have important consequences to our investors, such as:

- limiting our ability to obtain in the future additional financing we may need to fund future working capital, capital expenditures, product development, acquisitions or other corporate requirements; and
- requiring the dedication of a substantial portion of our cash flow from operations to the payment of principal and interest on our debt, which will reduce the availability of cash flow to fund working capital, capital expenditures, product development, acquisitions and other corporate requirements.

In addition, the instruments governing our debt contain financial and other restrictive covenants, which limit our operating flexibility and could prevent us from taking advantage of business opportunities. In addition, our failure to comply with these covenants may result in an event of default. If such event of default is not cured or waived, we may suffer adverse effects on our operations, business or financial condition, including acceleration of our debt.

We are vulnerable to interest rate risk with respect to our debt, which could lead to an increase in interest expense.

We are subject to interest rate risk in connection with our issuance of variable rate debt under our new global senior credit facility. Interest rate changes could increase the amount of our interest payments and thus, negatively impact our future earnings and cash flows. We estimate that our annual interest expense on our floating rate indebtedness would increase by \$3.2 million for each 1% increase in interest rates. See "ITEM 3. Quantitative and Qualitative Disclosures About Market Risk—Interest Rate Risk" under Part I of this report.

Allegations of the possibility of price fixing in the mattress industry could increase our costs or otherwise adversely affect our operations.

Our retail pricing policies are subject to antitrust regulations in the U.S. and abroad. If antitrust regulators in any jurisdiction in which we do business initiate investigations into or challenge our pricing or advertising

[Table of Contents](#)

policies, our efforts to respond could force us to divert management resources and we could incur significant unanticipated costs. If such an investigation were to result in a charge that our practices or policies were in violation of applicable antitrust laws or regulations, we could be subject to significant additional costs of defending such charges in a variety of venues and, ultimately, if there were a finding that we were in violation of antitrust laws or regulations, there could be an imposition of fines, damages for persons injured, as well as injunctive or other relief. Any requirement that we pay fines or damages could decrease our liquidity and profitability, and any investigation that requires significant management attention or causes us to change our business practices could disrupt our operations, also resulting in a decrease in our liquidity and profitability.

Our stock price is likely to continue to be volatile, your investment could decline in value, and we may incur significant costs from class action litigation.

The trading price of our common stock is likely to continue to be volatile and subject to wide price fluctuations. The trading price of our common stock may fluctuate significantly in response to various factors, including:

- actual or anticipated variations in our quarterly operating results, including those resulting from seasonal variations in our business;
- introductions or announcements of technological innovations or new products by us or our competitors;
- disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to patent our products and technologies;
- changes in estimates by securities analysts of our financial performance;
- conditions or trends in the specialty bedding industry, or the mattress industry generally;
- additions or departures of key personnel;
- announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
- announcements by our competitors of their quarterly operating results or announcements by our competitors of their views on trends in the bedding industry;
- regulatory developments in the U.S. and abroad;
- economic and political factors; and
- public announcements or filings with the SEC indicating that significant stockholders, directors or officers are selling shares of common stock.

In addition, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to operating performance. These broad market factors may seriously harm the market price of our common stock, regardless of our operating performance.

In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted. A securities class action suit against us could result in potential liabilities, substantial costs, and the diversion of our management's attention and resources, regardless of the outcome. See Part II, ITEM 1, Legal Proceedings.

Future sales of our common stock may depress our stock price.

The market price of our common stock could decline as a result of sales of substantial amounts of our common stock in the public market, or the perception that these sales could occur. In addition, these factors could make it more difficult for us to raise funds through future offerings of common stock. As of July 31, 2006, there were 82.9 million shares of our common stock outstanding. All of our shares of our common stock are freely

[Table of Contents](#)

transferable without restriction or further registration under the Securities Act of 1933, except for certain shares of our common stock which were purchased by our executive officers, directors, principal stockholders, and some related parties. During 2005, our two largest stockholders at the time, private equity funds that invested in the Company in 2002 in connection with the acquisition of our predecessor, made partial distributions to their investors totaling approximately 18.0 million shares of our common stock, and one of these stockholders also sold 5.3 million shares in June 2005. In February 2006, one of these stockholders made an additional distribution of the 5.8 million shares of remaining common stock that they held in the Company, and in May 2006 the other stockholder sold 6.3 million shares. Our largest stockholder continues to hold 15.6 million shares of our common stock and may choose to make additional distributions or sales of our common stock in the future.

In addition, on December 24, 2003, we registered up to 14,982,532 shares of our common stock reserved for issuance upon the exercise of options granted or reserved for grant under our 2002 Stock Option Plan, our 2003 Equity Incentive Plan and our 2003 Employee Stock Purchase Plan. Stockholders can sell these shares in the public market upon issuance, subject to restrictions under the securities laws and any applicable lock-up agreements.

Our current principal stockholder owns a large percentage of our common stock and could limit you from influencing corporate decisions.

As of July 31, 2006, our executive officers, directors, and our largest stockholder, and their respective affiliates, owned in the aggregate, approximately 26% of our outstanding common stock on a fully diluted basis, after giving effect to the vesting of all unvested options. These stockholders, as a group, are able to influence all matters requiring approval by our stockholders, including mergers, sales of assets, the election of all directors, and approval of other significant corporate transactions, in a manner with which you may not agree or that may not be in your best interest.

Provisions of Delaware law and our charter documents could delay or prevent an acquisition of us, even if the acquisition would be beneficial to you.

Provisions of Delaware law and our certificate of incorporation and by-laws could hamper a third party's acquisition of us, or discourage a third party from attempting to acquire control of us. You may not have the opportunity to participate in these transactions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock.

These provisions include:

- our ability to issue preferred stock with rights senior to those of the common stock without any further vote or action by the holders of our common stock;
- the requirements that our stockholders provide advance notice when nominating our directors; and
- the inability of our stockholders to convene a stockholders' meeting without the chairperson of the board, the president, or a majority of the board of directors first calling the meeting.

We do not anticipate paying dividends on our capital stock in the foreseeable future.

We do not anticipate paying any dividends in the foreseeable future, although as discussed elsewhere in this report we have adopted a share repurchase program. In addition, the terms of the instruments governing our existing debt and any future debt or credit facility may preclude us from paying any dividends.

[Table of Contents](#)

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

- (a) Not applicable.
- (b) Not applicable.
- (c) Issuer Purchases of Equity Securities

The following table sets forth purchases of our common stock for the six months ended June 30, 2006:

<u>Period</u>	<u>(a) Total number of shares purchased</u>	<u>(b) Average Price Paid per Share</u>	<u>(c) Total number of shares purchased as part of publicly announced plans or programs</u>	<u>(d) Maximum number of shares (or approximate dollar value) of shares that may yet be purchased under the plans or programs (in millions)</u>
April 1, 2006 – April 30, 2006	12,500	14.47	12,500	5.7
May 1, 2006 – May 31, 2006	1,754,424	13.94	1,754,424	21.2
June 1, 2006 – June 30, 2006	1,495,900	14.18	1,495,900	0.0
Total	3,262,824		3,262,824	

On October 18, 2005, our Board of Directors authorized the repurchase of up to \$80.0 million of the common stock. Share repurchases under this program may be made through open market transactions, negotiated purchases or otherwise, at times and in such amounts as we deemed appropriate. During 2005, we repurchased 6.8 million shares, at a total cost of \$76.0 million. We funded these share repurchases from borrowings under the Senior Credit Facility and funds from operations.

On January 25, 2006, our Board of Directors amended the share repurchase program described above to increase the total authorization by an additional \$100.0 million. On May 22, 2006, our Board of Directors further amended the share repurchase program to increase the total authorization under the share repurchase program by an additional \$40.0 million for a total authorization to purchase up to \$220.0 million of Tempur-Pedic International's common stock. During the six months ended June 30, 2006, we repurchased 11.3 million shares at a total cost of \$144.0 million. As of June 30, 2006, the Company had completed its existing share repurchase authorization. The share repurchases were funded from borrowings under the 2005 Senior Credit Facility and funds from operations.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Tempur-Pedic International's annual meeting of stockholders was held on April 28, 2006. Proposals 1 and 2, the only Proposals presented for a vote at the meeting, were approved. The results are as follows:

Proposal 1

The following directors were elected at the meeting to serve a one-year term as directors:

	<u>For</u>	<u>Authority Withheld</u>
Jeffrey S. Barber	77,854,026	143,696
H. Thomas Bryant	77,867,514	130,208
Francis A. Doyle	77,490,883	506,839
Sir Paul Judge	77,858,296	139,424
Nancy F. Koehn	77,866,869	130,853
Christopher A. Mastro	77,720,958	276,764
P. Andrews McLane	77,853,407	144,315
Robert Trussell, Jr.	77,865,695	132,027

[Table of Contents](#)

Proposal 2

Ratification of appointment of Ernst & Young LLP as the Company's independent auditors for fiscal year 2005.

<u>For</u>	<u>Against</u>	<u>Abstained</u>
77,129,568	840,241	27,913

The Proposals above are described in detail in the Company's definitive proxy statement dated March 27, 2006, for the Annual Meeting of Stockholders held on April 28, 2006.

ITEM 5. OTHER INFORMATION

(a) Not applicable.

(b) Not applicable.

ITEM 6. EXHIBITS

The following is an index of the exhibits included in this report:

10.1	Amended and Restated Employment Agreement dated as of June 29, 2006 between Tempur World, Inc. and H. Thomas Bryant
10.2	Option Agreement dated as of June 26, 2006 between Tempur-Pedic International Inc. and H. Thomas Bryant
10.3	Option Agreement dated May 2, 2005 between Tempur-Pedic International Inc. and Bhaskar Rao.
10.4	Option Agreement dated October 25, 2005 between Tempur-Pedic International Inc. and Bhaskar Rao.
10.5	Option Agreement dated February 16, 2006 between Tempur-Pedic International Inc. and Bhaskar Rao.
10.6	Option Agreement dated May 11, 2006 between Tempur-Pedic International Inc. and Bhaskar Rao.
10.7	Option Agreement dated June 28, 2006 between Tempur-Pedic International Inc. and David Montgomery.
10.8	Option Agreement dated June 28, 2006 between Tempur-Pedic International Inc. and Dale E. Williams.
10.9	Form of Option Agreement under the 2003 Equity Incentive Plan
31.1	Certification of Chief Executive Officer, pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer, pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**EMPLOYMENT AND NON-COMPETITION AGREEMENT
(Tom Bryant)**

THIS EMPLOYMENT AND NON-COMPETITION AGREEMENT (the "Agreement") is executed as of this 29th day of June, 2006, and effective as of April 28, 2006 (the "Effective Date"), by and between Tempur-Pedic International, Inc., a Delaware corporation (the "Company"), and Tom Bryant, an individual ("Employee").

RECITALS

The Employee is currently a party to an Amended and Restated Employment Agreement, dated as of October 4, 2002 with a subsidiary of the Company (the "Former Agreement"). Prior to the Effective Date the Employee had held the position of President of the Company, and on the Effective Date the Employee was also named the Chief Executive Officer of the Company. The Company and the Employee are entering into this Agreement in order to evidence the terms under which the Employee will be employed by the Company from and after the Effective Date. This Agreement supersedes and replaces the terms of the Former Agreement.

In consideration of the premises and the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Company and Employee,

IT IS HEREBY AGREED AS FOLLOWS:

**ARTICLE I
EMPLOYMENT**

1.1 Term of Employment. As of the Effective Date, the Company agrees to employ Employee as the President and Chief Executive Officer of the Company, and Employee accepts employment by the Company, for the period commencing on the Effective Date and ending on April 30, 2008 (the "Initial Term"), subject to earlier termination as set forth in Article III below. Unless earlier terminated in accordance with Article III, following the expiration of the Initial Term, this Agreement shall be automatically renewed for successive one-year periods (collectively, the "Renewal Terms"; individually, a "Renewal Term") unless, at least ninety (90) days prior to the expiration of the Initial Term or the then current Renewal Term, either party provides the other with a written notice of intention not to renew, in which case the Employee's employment with the Company, and the Company's obligations hereunder, shall terminate as of the end of the Initial Term or said Renewal Term, as applicable. Except as otherwise expressly provided herein, the terms and conditions of this Agreement during any Renewal Term shall be the same as the terms in effect immediately prior to such renewal, subject to any such changes or modifications as mutually may be agreed between the parties as evidenced in a written instrument signed by both the Company and Employee.

1.2 Position and Duties. Employee shall be employed in the position of President and Chief Executive Officer. In such capacity, Employee shall be subject to the authority of, and shall report to, the Company's Board of Directors Employee shall devote Employee's entire business time, loyalty, attention and energies exclusively to the business interests of the Company while employed by the Company, and shall perform his duties and responsibilities diligently and to the best of his ability.

**ARTICLE II
COMPENSATION AND OTHER BENEFITS**

2.1 Base Salary. The Company shall pay Employee an annual salary of \$600,000 ("Base Salary"), payable in accordance with the normal payroll practices of the Company. The Employee's Base Salary will be reviewed and be subject to adjustment by the Board of Directors or its Compensation Committee on or about January 1 of each year beginning with January 1, 2007.

2.2 Performance Bonus. Employee will be eligible to earn an annual performance-based bonus based on a formula approved by the Company's Board of Directors or its Compensation Committee and incorporated herein by this reference for 2006 and each subsequent full or pro-rata portion of the fiscal year during which Employee is employed by the Company (a "Bonus Year"), the terms and conditions of which as well as Employee's entitlement thereto shall be determined annually in the sole discretion of the Company's Board of Directors or its Compensation Committee (the "Performance Bonus"). The amount of the Performance Bonus will vary based on the achievement of performance criteria in the formula established by the Company's Board of Directors or Compensation Committee, but the formula will be set to target a Performance Bonus equal to 100% of Base Salary as of January 1st of the Bonus Year (\$600,000 for 2006) if the performance criteria in the formula are met, and the actual bonus awarded based on the performance criteria may be more or less than the target amount of 100%.

2.3 Benefit Plans. Employee will be eligible to participate in the Company's retirement plans that are qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended, and in the Company's employee welfare benefit plans that are generally applicable to all executive employees of the Company (the "Plans"), in accordance with the terms and conditions thereof.

2.4 Expenses. The Company shall reimburse Employee for all authorized and approved expenses incurred in the course of the performance of Employee's duties and responsibilities pursuant to this Agreement and consistent with the Company's policies with respect to travel, entertainment and miscellaneous expenses, and the requirements with respect to the reporting of such expenses.

2.5 Automobile Allowance. The Company shall pay to Employee an automobile allowance of \$600.00 per month.

2.6 Vacation. Employee shall be entitled to vacation in any calendar year in accordance with the Company's general vacation policies for senior executive employees.

2.7 Grant of Stock Options. Not later than June 30, 2006 the Company will grant Employee options to purchase 700,000 shares of the Company's common stock on terms to be determined by the Compensation Committee, which will include the terms outlined on Annex A.

ARTICLE III TERMINATION

3.1 Right to Terminate; Automatic Termination.

(a) Termination by Company Without Cause. Subject to Section 3.2, the Company may terminate Employee's employment and all of the Company's obligations under this Agreement at any time and for any reason.

(b) Termination by Employee for Good Reason. Subject to Section 3.2, Employee may terminate his employment obligation hereunder (but not his obligation under Article IV hereof) for "Good Reason" (as hereinafter defined) if Employee gives written notice thereof to the Company within thirty (30) days of the event he deems to constitute Good Reason (which notice shall specify the grounds upon which such notice is given) and the Company fails, within 30 days of receipt of such notice, to cure or rectify the grounds for such Good Reason termination set forth in such notice. "Good Reason" shall mean any of the following: (i) relocation of Employee's principal workplace over 60 miles from the Company's existing workplaces without the consent of Employee (which consent shall not be unreasonably withheld, delayed or conditioned), (ii) the Employee is demoted from the position of Chief Executive Officer of the Company or (iii) the Company's

material breach of this Agreement which is not cured within 30 days after receipt by the Company from Employee of written notice of such breach.

(c) Termination by Company For Cause. Subject to Section 3.2, the Company may terminate Employee's employment and all of the Company's obligations under this Agreement at any time "For Cause" (as defined below) by giving notice to Employee stating the basis for such termination, effective immediately upon giving such notice or at such other time thereafter as the Company may designate. "For Cause" shall mean any of the following: (i) Employee's willful and continued failure to substantially perform the reasonably assigned duties with the Company which are consistent with Employee's position and job description referred to in this Agreement, other than any such failure resulting from incapacity due to physical or mental illness, after a written notice is delivered to Employee by the Board of Directors of the Company which specifically identifies the manner in which Employee has not substantially performed the assigned duties, (ii) Employee's willful engagement in illegal conduct which is materially and demonstrably injurious to the Company, (iii) Employee's conviction by a court of competent jurisdiction of, or his pleading guilty or nolo contendere to, any felony, or (iv) Employee's commission of an act of fraud, embezzlement, or misappropriation against the Company, including, but not limited to, the offer, payment, solicitation or acceptance of any unlawful bribe or kickback with respect to the Company's business. For purposes of this paragraph, no act, or failure to act, on Employee's part shall be considered "willful" unless done, or omitted to be done, in knowing bad faith and without reasonable belief that the action or omission was in, or not opposed to, the best interests of the Company. Any act, or failure to act, expressly authorized by a resolution duly adopted by the Board of Directors or based upon the written advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, in good faith and in the best interests of the Company. Notwithstanding the foregoing, Employee shall not be deemed to have been terminated For Cause unless and until there shall have been delivered to Employee a copy of a resolution, duly adopted by the Board of Directors at a meeting of the Board called and held for such purpose (after reasonable notice to Employee and an opportunity for Employee, together with Employee's counsel, to be heard before the Board at a duly called meeting at which a quorum is present), finding that in the good faith opinion of the Board of Directors Employee committed the conduct set forth above in (i), (ii), (iii) or (iv) of this Section 3.1 (c) and specifying the particulars thereof in detail.

(d) Termination Upon Death or Disability. Subject to Section 3.2, Employee's employment and the Company's obligations under this Agreement shall terminate: (i) automatically, effective immediately and without any notice being necessary, upon Employee's death; and (ii) in the event of the disability of Employee, by the Company giving notice of termination to Employee. For purposes of this Agreement, "disability" means the inability of Employee, due to a physical or mental impairment, for 90 days (whether or not consecutive) during any period of 360 days, to perform, with reasonable accommodation, the essential functions of the work contemplated by this Agreement. In the event of any dispute as to whether Employee is disabled, the matter shall be determined by the Company's Board of Directors in consultation with a physician selected by the Company's health or disability insurer or another physician mutually satisfactory to the Company and the Employee. The Employee shall cooperate with the efforts to make such determination or be subject to immediate discharge. Any such determination shall be conclusive and binding on the parties. Any determination of disability under this Section 3.1 is not intended to alter any benefits any party may be entitled to receive under any long-term disability insurance policy carried by either the Company or Employee with respect to Employee, which benefits shall be governed solely by the terms of any such insurance policy. Nothing in this subsection shall be construed as limiting or altering any of Employee's rights under State workers compensation laws or State or federal Family and Medical Leave laws.

3.2 Rights Upon Termination.

(a) Section 3.1(a) and 3.1(b) Termination. If Employee's employment terminates pursuant to Section 3.1(a) or 3.1(b) hereof, Employee shall have no further rights against the Company hereunder, except for the right to receive, following execution of a release and waiver in form satisfactory to the Company, (i) any unpaid Base Salary, the value of any accrued but unused vacation, a pro-rata portion (based on the number of days of the Bonus Year prior to the effective date of termination) of any Performance Bonus that would be payable with respect to the Bonus Year in which the termination occurs, calculated based on the 100% target amount referred to in Section 2.2, and any stock options to which the Employee is entitled under his stock option agreements, (ii) payment of Base Salary for the duration of the Initial Term or the Renewal Term, as

applicable, but in any event not less than a period of one year from the effective date of termination (the “Severance Period”), payable in accordance with the normal payroll practices of the Company, (iii) reimbursement of expenses to which Employee is entitled under Section 2.4 hereof, and (iv) continuation of the welfare plans of the Company as detailed in Section 2.3 hereof for the duration of the Severance Period.

(b) Section 3.1(c) and 3.1(d) Termination; Voluntary Termination by Employee not for Good Reason. If Employee’s employment is terminated pursuant to Sections 3.1(c) or 3.1(d) hereof, or if Employee quits employment (other than for Good Reason) notwithstanding the terms of this Agreement, Employee or Employee’s estate shall have no further rights against the Company hereunder, except for the right to receive, following execution of a release and waiver in form satisfactory to the Company, (i) any unpaid Base Salary, (ii) reimbursement of expenses to which Employee is entitled under Section 2.4 hereof, and (iii) in the case of a termination pursuant to Section 3.1(d) hereof, the value of any accrued but unused vacation, a pro-rata portion (based on the number of days of the Bonus Year prior to the effective date of termination) of any Performance Bonus that would be payable with respect to the Bonus Year in which the termination occurs, calculated at the 100% target level referred to in Section 2.2, and any stock options to which the Employee is entitled under his stock option agreements.

(c) Non-Renewal. In the event that either the Company or the Employee elect not to renew the term of this Agreement as provided in Section 1.1, then the Employee shall have no further rights against the Company hereunder, except the right to receive, following execution of a release and waiver in form satisfactory to the Company, the items described in clauses (i)-(iii) of paragraph (b) above.

ARTICLE IV

CONFIDENTIALITY; NON-COMPETITION; NONSOLICITATION

4.1 Covenants Regarding Confidential Information, Trade Secrets and Other Matters. Employee covenants and agrees as follows:

(a) Definitions. For purposes of this Agreement, the following terms are defined as follows:

(1) “Trade Secret” means all information possessed by or developed for the Company or any of its subsidiaries, including, without limitation, a compilation, program, device, method, system, technique or process, to which all of the following apply: (i) the information derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and (ii) the information is the subject of efforts to maintain its secrecy that are reasonable under the circumstances.

(2) “Confidential Information” means information, to the extent it is not a Trade Secret, which is possessed by or developed for the Company or any of its subsidiaries and which relates to the Company’s or any of its subsidiaries’ existing or potential business or technology, which information is generally not known to the public and which information the Company or any of its subsidiaries seeks to protect from disclosure to its existing or potential competitors or others, including, without limitation, for example: business plans, strategies, existing or proposed bids, costs, technical developments, existing or proposed research projects, financial or business projections, investments, marketing plans, negotiation strategies, training information and materials, information generated for client engagements and information stored or developed for use in or with computers. Confidential Information also includes information received by the Company or any of its subsidiaries from others which the Company or any of its subsidiaries has an obligation to treat as confidential.

(b) Nondisclosure of Confidential Information. Except as required in the conduct of the Company’s or any of its subsidiaries’ business or as expressly authorized in writing on behalf of the Company or any of its subsidiaries, Employee shall not use or disclose, directly or indirectly, any Confidential Information during the period of his employment with the Company. In addition, following the termination for any reason of Employee’s employment with the Company, Employee shall not use or disclose, directly or indirectly, any

Confidential Information. This prohibition does not apply to Confidential Information after it has become generally known in the industry in which the Company conducts its business. This prohibition also does not prohibit Employee's use of general skills and know-how acquired during and prior to employment by the Company, as long as such use does not involve the use or disclosure of Confidential Information or Trade Secrets.

(c) Trade Secrets. During Employee's employment by the Company, Employee shall do what is reasonably necessary to prevent unauthorized misappropriation or disclosure and threatened misappropriation or disclosure of the Company's or any of its subsidiaries' Trade Secrets and, after termination of employment, Employee shall not use or disclose the Company's or any of its subsidiaries' Trade Secrets as long as they remain, without misappropriation, Trade Secrets.

(d) The provisions of paragraphs (b) and (c) above will not be deemed to prohibit any disclosure that is required by law or court order, provided that Employee has not intentionally taken actions to trigger such required disclosure and the Company is given reasonable prior notice and an opportunity to contest or minimize such disclosure.

4.2 Non-competition.

(a) During Employment. During Employee's employment hereunder, Employee shall not engage, directly or indirectly, as an employee, officer, director, partner, manager, consultant, agent, owner (other than a minority shareholder or other equity interest of not more than 1% of a company whose equity interests are publicly traded on a nationally recognized stock exchange or over-the-counter) or in any other capacity, in any competition with the Company or any of its subsidiaries.

(b) Subsequent to Employment. For a two year period following the termination of Employee's employment for any reason or without reason, Employee shall not in any capacity (whether in the capacity as an employee, officer, director, partner, manager, consultant, agent or owner (other than a minority shareholder or other equity interest of not more than 1% of a company whose equity interests are publicly traded on a nationally recognized stock exchange or over-the-counter), directly or indirectly advise, manage, render or perform services to or for any person or entity which is engaged in a business competitive to that of the Company or any of its subsidiaries within any geographical location wherein the Company or any of its subsidiaries produces, sells or markets its goods and services at the time of such termination or within a one-year period prior to such termination.

4.3 Nonsolicitation. For a two year period following the termination of Employee's employment for any reason or without reason, Employee shall not solicit or induce any person who was an employee of the Company or any of its subsidiaries on the date of Employee's termination or within three months prior to leaving his or her employment with the Company or any of its subsidiaries.

4.4 Return of Documents. Immediately upon termination of employment, Employee will return to the Company, and so certify in writing to the Company, all the Company's or any of its subsidiaries' papers, documents and things, including information stored for use in or with computers and software applicable to the Company's and its subsidiaries' business (and all copies thereof), which are in Employee's possession or under Employee's control, regardless whether such papers, documents or things contain Confidential Information or Trade Secrets.

4.5 No Conflicts. To the extent that they exist, Employee will not disclose to the Company any of Employee's previous employer's confidential information or trade secrets. Further, Employee represents and warrants that Employee has not previously assumed any obligations inconsistent with those of this Agreement and that employment by the Company does not conflict with any prior obligations to third parties.

4.6 Agreement on Fairness. Employee acknowledges that: (i) this Agreement has been specifically bargained between the parties and reviewed by Employee, (ii) Employee has had an opportunity to obtain legal counsel to review this Agreement, and (iii) the covenants made by and duties imposed upon Employee hereby are fair, reasonable and minimally necessary to protect the legitimate business interests of the Company, and

such covenants and duties will not place an undue burden upon Employee's livelihood in the event of termination of Employee's employment by the Company and the strict enforcement of the covenants contained herein.

4.7 Equitable Relief and Remedies. Employee acknowledges that any breach of this Agreement will cause substantial and irreparable harm to the Company for which money damages would be an inadequate remedy. Accordingly, notwithstanding the provisions of Article V below, the Company shall in any such event be entitled to obtain injunctive and other forms of equitable relief to prevent such breach and the prevailing party shall be entitled to recover from the other, the prevailing party's costs (including, without limitation, reasonable attorneys' fees) incurred in connection with enforcing this Agreement, in addition to any other rights or remedies available at law, in equity, by statute or pursuant to Article V below.

ARTICLE V
AGREEMENT TO SUBMIT ALL EXISTING OR FUTURE DISPUTES
TO BINDING ARBITRATION

The Company and Employee agree that any controversy or claim arising out of or related to this Agreement or Employee's employment with or termination by the Company that is not resolved by the parties shall be settled by arbitration administered by the American Arbitration Association under its National Rules for the Resolution of Employment Disputes. Said arbitration shall be conducted in Lexington, Kentucky. The parties further agree that the arbitrator may resolve issues of contract interpretation as well as law and award damages, if any, to the extent provided by the Agreement or applicable law. The parties agree that the costs of the arbitrator's services shall be borne by the Company. The parties further agree that the arbitrator's decision will be final and binding and enforceable in any court of competent jurisdiction. In addition to the A.A.A.'s Arbitration Rules and unless otherwise agreed to by the parties, the following rules shall apply:

(a) Each party shall be entitled to discovery exclusively by the following means: (i) requests for admission, (ii) requests for production of documents, (iii) up to 15 written interrogatories (with any subpart to be counted as a separate interrogatory), and (iv) depositions of no more than six individuals.

(b) Unless the arbitrator finds that delay is reasonably justified or as otherwise agreed to by the parties, all discovery shall be completed, and the arbitration hearing shall commence within five months after the appointment of the arbitrator.

(c) Unless the arbitrator finds that delay is reasonably justified, the hearing will be completed, and an award rendered within 30 days of commencement of the hearing.

The arbitrator's authority shall include the ability to render equitable types of relief and, in such event, any aforesaid court may enter an order enjoining and/or compelling such actions or relief ordered or as found by the arbitrator. The arbitrator also shall make a determination regarding which party's legal position in any such controversy or claim is the more substantially correct (the "Prevailing Party") and the arbitrator shall require the other party to pay the legal and other professional fees and costs incurred by the Prevailing Party in connection with such arbitration proceeding and any necessary court action.

Notwithstanding the foregoing provisions of this Article V, the parties expressly agree that a court of competent jurisdiction may enter a temporary restraining order or an order enjoining a breach of Article IV of this Agreement without submission of the underlying dispute to an arbitrator. Such remedy shall be cumulative and nonexclusive, and shall be in addition to any other remedy to which the parties may be entitled.

ARTICLE VI
GENERAL PROVISIONS

6.1 Notices. Any and all notices provided for in this Agreement shall be given in writing and shall be

deemed given to a party at the earlier of (i) when actually delivered to such party, or (ii) when mailed to such party by registered or certified mail (return receipt requested) or sent to such party by courier, confirmed by receipt, and addressed to such party at the address designated below for such party as follows (or to such other address for such party as such party may have substituted by notice pursuant to this Section 6.1):

(a) If to the Company:

Tempur-Pedic International, Inc.
1713 Jaggie Fox Way
Lexington, KY 40511
Attention: Board of Directors

(b) If to Employee:

Tom Bryant
c/o Tempur-Pedic International, Inc.
1713 Jaggie Fox Way
Lexington, KY 40511

6.2 Entire Agreement. This Agreement contains the entire understanding and the full and complete agreement of the parties and, effective as of the Closing Date, supersedes and replaces any prior understandings and agreements among the parties with respect to the subject matter hereof (including, without limitation, the Former Agreement). The Employee hereby acknowledges and agrees that (a) no amounts are owed to him under the Former Agreement, and (b) effective as of the Effective Date, the Former Agreement shall terminate and be of no further force or effect.

6.3 Amendment. This Agreement may be altered, amended or modified only in a writing, signed by both of the parties hereto. Headings included in this Agreement are for convenience only and are not intended to limit or expand the rights of the parties hereto. References to Sections herein shall mean sections of the text of this Agreement, unless otherwise indicated.

6.4 Assignability. This Agreement and the rights and duties set forth herein may not be assigned by either of the parties without the express written consent of the other party. This Agreement shall be binding on and inure to the benefit of each party and such party's respective heirs, legal representatives, successors and assigns.

6.5 Severability. If any court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then such invalidity or unenforceability shall have no effect on the other provisions hereof, which shall remain valid, binding and enforceable and in full force and effect, and such invalid or unenforceable provision shall be construed in a manner so as to give the maximum valid and enforceable effect to the intent of the parties expressed therein.

6.6 Waiver of Breach. The waiver by either party of the breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by either party.

6.7 Governing Law; Construction. This Agreement shall be governed by the internal laws of the State of Kentucky, without regard to any rules of construction concerning the party responsible for the drafting hereof.

6.8 Tax Compliance. The Company may withhold from any amounts payable hereunder any amounts required to be withheld under federal, state or local law and any other deductions authorized by Employee. If any other payment otherwise due hereunder would be, when otherwise due, subject to additional taxes and interest under Section 409A of the Internal Revenue Code of 1986, as amended, then such payment shall be deferred to the extent required to avoid such additional taxes and interest.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year written above.

COMPANY:

TEMPUR-PEDIC INTERNATIONAL, INC.

EMPLOYEE:

/s/ H. THOMAS BRYANT

WITNESSED BY:

Date:

TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN
STOCK OPTION AGREEMENT
(TOM BRYANT)

THIS AGREEMENT dated as of June 26, 2006, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out (the "Optionee").

1. **Grant of Option.** Pursuant and subject to the Company's 2003 Equity Incentive Plan (as the same may be amended from time to time, the "Plan"), the Company grants to the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of seven hundred thousand (700,000) shares (the "Optioned Shares") of the Company's common stock, par value \$0.01 per share (the "Stock"), at a price of \$13.92 per share. The Grant Date of this Option shall be June 26, 2006.

2. **Character of Option.** This Option is not to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. **Duration of Option.** Subject to the following sentence, this Option shall expire at 5:00 p.m. on June 26, 2016. However, if the Optionee's employment ends before that date (including because the Optionee's employer ceases to be an Affiliate), this Option shall expire on the earliest date specified in whichever of the following applies:

(a) If the Optionee's employment terminates pursuant to Section 3.1(a) ("Termination by Company Without Cause") or 3.1(b) ("Termination by Employee for Good Reason") of the Employment and Noncompetition Agreement between the Optionee and the Company dated as of June 26, 2006 (the "Employment Agreement"), then ninety (90) days after the date of such termination of employment;

(b) If the Optionee's employment is terminated pursuant to Section 3.1(c) ("Termination by the Company for Cause") of the Employment Agreement, or if Optionee terminates his employment (other than pursuant to Section 3.1(b) of the Employment Agreement) or if the Optionee or the Company elects not to renew the term of the Employment Agreement, as provided in Section 1.1 of the Employment Agreement, then on the date of the termination of employment; or

(c) If the Optionee's employment terminates pursuant to Section 3.1(d) ("Termination Upon Death or Disability") of the Employment Agreement, then on the first anniversary of the date employment ends.

This Option shall expire as described above based on the Optionee's termination of employment notwithstanding that the Optionee continues in association with the Company or an Affiliate in another capacity. The date of the Optionee's termination or cessation of employment with the Company and its Affiliates shall be referred to herein as the "Termination Date."

4. **Vesting and Exercise of Option.**

(a) The Optionee shall have the right to exercise this Option for all or a portion of the Optioned Shares which have become Vested Optioned Shares as of the date of exercise in accordance with this Section 4. Initially, none of the Optioned Shares shall be considered "Vested Optioned Shares" and all of the Optioned Shares shall be considered "Unvested Optioned Shares". On the first anniversary date hereof prior to a Termination Date, twenty five percent (25%) of the Optioned Shares shall become "Vested Optioned Shares" as

set forth below, and on each quarterly anniversary of the Grant Date thereafter prior to a Termination Date, an additional six and a quarter percent (6.25%) of the Optioned Shares shall become “Vested Optioned Shares”, such that all of the Optioned Shares shall be Vested Optioned Shares as of and after June 26, 2010 if a Termination Date does not occur prior to such date. The table set forth below identifies the number of Optioned Shares and the applicable vesting dates pursuant to which the Optionee may exercise this Option.

<u>Date</u>	<u>Percentage</u>	<u>Vested Optioned Shares</u>
June 26, 2007	25%	175,000
September 26, 2007	6.25%	218,750
December 26, 2007	6.25%	262,500
March 26, 2008	6.25%	306,250
June 26, 2008	6.25%	350,000
September 26, 2008	6.25%	393,750
December 26, 2008	6.25%	437,750
March 26, 2009	6.25%	481,250
June 26, 2009	6.25%	525,000
September 26, 2009	6.25%	568,750
December 26, 2010	6.25%	612,500
March 26, 2010	6.25%	656,250
June 26, 2010	6.25%	700,000

(b) If this Option terminates pursuant to Section 3(a) of this Agreement, then that number of Unvested Optioned Shares that would otherwise vest and become Vested Optioned Shares during the one year period after the Termination Date shall immediately vest and become Vested Optioned Shares as of the Termination Date, but no additional Unvested Optioned Shares will become Vested Optioned Shares after such date.

(c) If this Option terminates pursuant to Section 3(c) of this Agreement, then fifty percent (50%) of any Optioned Shares that were Unvested Optioned Shares on such date shall immediately vest and become Vested Optioned Shares as of the Termination Date, but no additional Unvested Optioned Shares shall become Vested Optioned Shares after such date.

(d) During any period that this Option remains outstanding after the Termination Date, the Optionee may only exercise such Option to the extent provided in this Section 4 of this Agreement. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. The exercise price due on exercise may be paid by delivering other shares of Stock of equivalent Market Value provided the Optionee has owned such shares of Stock for at least six months.

5. **Transfer of Option.** Except as provided in Section 6.4 of the Plan, this Option may not be transferred except by will or the laws of descent and distribution, and, during the Optionee's lifetime, only the Optionee may exercise this Option.

6. **Change of Control Acceleration.** Section 9 of the Plan ("Change of Control") will not apply to this Option. However, as provided in Section 7.1(d) of the Plan, the Committee retains the right to accelerate this Option in whole or in part at any time.

7. **Incorporation of Plan Terms.** This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 of the Plan ("Settlement of Awards"). Capitalized terms used but not defined herein shall have the meaning assigned under the Plan.

8. **Miscellaneous.** This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof, and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee. This Agreement may be executed in one or more counterparts all of which together shall constitute one instrument.

9. **Tax Consequences.** The Company makes no representation or warranty as to the tax treatment of this Option or the exercise of this Option or upon the Optionee's sale or other disposition of the Optioned Shares. The Optionee should rely on his own tax advisors for such advice.

10. **Certain Remedies.**

(a) If at any time within two years after termination of the Optionee's employment with the Company and its Affiliates any of the following occur:

(i) the Optionee unreasonably refuses to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;

(ii) the Optionee accepts employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or the Optionee otherwise engages in competition with the Company or its Affiliates;

(iii) the Optionee acts against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting his new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;

(iv) the Optionee fails to protect and safeguard while in the Optionee's possession or control, or surrender to the Company upon termination of the Optionee's employment with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by the Optionee;

(v) the Optionee solicits or encourages any person or enterprise with which he had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) the Optionee breaches any confidentiality obligations he has to the Company or an Affiliate, the Optionee fails to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, the Optionee uses confidential information of the Company or its Affiliates

for his own benefit or gain, or the Optionee discloses or other misuses confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

(1) this Option shall terminate and be cancelled effective as of the date on which the Optionee entered into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Agreement or the Plan;

(2) any stock acquired and held by the Optionee pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$13.92 per share; and

(3) any gain realized by the Optionee from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by the Optionee to the Company;

(b) The term "Applicable Period" shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to the Optionee's termination of employment with the Company or any Affiliate and ending two years from the Optionee's termination of employment with the Company or any Affiliate.

(c) The term "Competitive Enterprise" shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company's products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended from time to time upon notice to the Optionee. At any time the Optionee may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from the Optionee about the enterprise, and the determination will be valid for a period of ninety (90) days from the Termination Date.

11. **Right of Set Off.** By executing this Agreement, the Optionee consents to a deduction from any amounts the Company or any Affiliate owes the Optionee from time to time, to the extent of the amounts the Optionee owes the Company under Section 10 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to the Optionee to the extent that the exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount the Optionee owes the Company, calculated as set forth above, the Optionee agrees to pay immediately the unpaid balance to the Company upon the Company's demand.

12. **Nature of Remedies.**

(a) The remedies set forth in Sections 10 and 11 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 10(a). The Company shall also be entitled to issue stop transfer instructions to the Company's stock transfer agent in the event the Company believes that any event referred to in Section 10(a) has occurred or is reasonably likely to occur.

TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN
STOCK OPTION AGREEMENT
(Bhaskar Rao)

THIS AGREEMENT dated as of May 2, 2005, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and Mr. Bhaskar Rao, residing at the address identified below (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan as attached hereto (as the same may be amended from time to time, the "Plan"), the Company grants to you, the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of 25,000 shares (the "Optioned Shares") of the common stock, par value \$.01 per share, of the Company (the "Stock"), at a price per share equal to \$19.22. The Grant Date of this Option is as of May 2, 2005.

2. Character of Option. Subject to the limitations set forth in Section 7.1(f) of the Plan, this Option is to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on May 2, 2015. However, if your employment or other association with the Company and its Affiliates ends before that date (including because your employer ceased to be an Affiliate), this Option shall expire at 5:00 p.m. on May 2, 2015 or, if earlier, the date specified in whichever of the following applies:

(a) If the termination of your employment or other association is on account of your death or disability, the first anniversary of the date your employment ends.

(b) If the termination of your employment or other association is due to any other reason, three (3) months after your employment or other association ends.

4. Exercise of Option.

(a) Until this Option expires, you may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after your employment or other association with the Company and its Affiliates ends, including because your employer ceased to be an Affiliate, you may exercise it only to the extent it was exercisable immediately prior to the end of your employment or other association. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. You may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided you have owned such shares of Stock for at least six months.

<u>Number of Shares in Each Installment</u>	<u>Initial Exercise Date for Shares in Installment</u>
6,250	May 2, 2006
1,562	August 2, 2006
1,563	November 2, 2006
1,562	February 2, 2007
1,563	May 2, 2007
1,562	August 2, 2007
1,563	November 2, 2007
1,562	February 2, 2008
1,563	May 2, 2008

1,562
1,563
1,562
1,563

August 2, 2008
November 2, 2008
February 2, 2009
May 2, 2009

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, you may not transfer this Option except by will or the laws of descent and distribution, and, during your lifetime, only you may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 (Settlement of Awards).

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of you. Capitalized terms used but not defined herein shall have the meaning assigned under the Plan. This Agreement may be executed in one or more counterparts all of which together shall constitute but one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment to you of your receipt or exercise of this Option or upon your sale or other disposition of the Optioned Shares. You should rely on your own tax advisors for such advice. In particular, you acknowledge that in any event, as a result of the limitations set forth in Section 7.1(f) of the Plan, a significant portion of this Option will not be treated as an Incentive Option.

TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN
STOCK OPTION AGREEMENT
(Bhaskar Rao)

THIS AGREEMENT dated as of October 25, 2005, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and Mr. Bhaskar Rao, residing at the address identified below (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan as attached hereto (as the same may be amended from time to time, the "Plan"), the Company grants to you, the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of 25,000 shares (the "Optioned Shares") of the common stock, par value \$.01 per share, of the Company (the "Stock"), at a price per share equal to \$10.66. The Grant Date of this Option is as of October 25, 2005.

2. Character of Option. Subject to the limitations set forth in Section 7.1(f) of the Plan, this Option is to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on October 25, 2015. However, if your employment or other association with the Company and its Affiliates ends before that date (including because your employer ceased to be an Affiliate), this Option shall expire at 5:00 p.m. on October 25, 2015 or, if earlier, the date specified in whichever of the following applies:

(a) If the termination of your employment or other association is on account of your death or disability, the first anniversary of the date your employment ends.

(b) If the termination of your employment or other association is due to any other reason, three (3) months after your employment or other association ends.

4. Exercise of Option.

(a) Until this Option expires, you may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after your employment or other association with the Company and its Affiliates ends, including because your employer ceased to be an Affiliate, you may exercise it only to the extent it was exercisable immediately prior to the end of your employment or other association. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. You may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided you have owned such shares of Stock for at least six months.

<u>Number of Shares in Each Installment</u>	<u>Initial Exercise Date for Shares in Installment</u>
6,250	October 25, 2006
1,562	January 25, 2006
1,563	April 25, 2007
1,562	July 25, 2007
1,563	October 25, 2007
1,562	January 25, 2007
1,563	April 25, 2008
1,562	July 25, 2008

1,563	October 25, 2008
1,562	January 25, 2008
1,563	April 25, 2009
1,562	July 25, 2009
1,563	October 25, 2009

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, you may not transfer this Option except by will or the laws of descent and distribution, and, during your lifetime, only you may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 (Settlement of Awards).

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of you. Capitalized terms used but not defined herein shall have the meaning assigned under the Plan. This Agreement may be executed in one or more counterparts all of which together shall constitute but one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment to you of your receipt or exercise of this Option or upon your sale or other disposition of the Optioned Shares. You should rely on your own tax advisors for such advice. In particular, you acknowledge that in any event, as a result of the limitations set forth in Section 7.1(f) of the Plan, a significant portion of this Option will not be treated as an Incentive Option.

**TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN**

**Stock Option Agreement
(Bhaskar Rao)**

THIS AGREEMENT dated as of February 16, 2006, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan as attached hereto (as the same may be amended from time to time, the "Plan"), the Company grants to you, the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of 35,000 shares (the "Optioned Shares") of the common stock, par value \$.01 per share, of the Company (the "Stock"), at a price of \$12.37 per share. The Grant Date of this Option is as of December 15, 2005.

2. Character of Option. This Option is not to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on December 14, 2015. However, if your employment or other association with the Company and its Affiliates ends before that date (including because your employer ceased to be an Affiliate), this Option shall expire at 5:00 p.m. on December 14, 2015 or, if earlier, the date specified in whichever of the following applies:

(a) If the termination of your employment or other association is on account of your death or disability, the first anniversary of the date your employment ends.

(b) If the termination of your employment or other association is due to any other reason, three (3) months after your employment or other association ends.

4. Exercise of Option.

(a) Until this Option expires, you may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after your employment or other association with the Company and its Affiliates ends, including because your employer ceased to be an Affiliate, you may exercise it only to the extent it was exercisable immediately prior to the end of your employment or other association. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. You may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided you have owned such shares of Stock for at least six months.

Number of Shares in Each Installment	Initial Exercise Date for Shares in Installment
8,750	December 15, 2006
8,750	December 15, 2007
8,750	December 15, 2008
8,750	December 15, 2009

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, you may not transfer this Option except by will or the laws of descent and distribution, and, during your lifetime, only you may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 (Settlement of Awards).

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of you. Capitalized terms used but not defined herein shall have the meaning assigned under the Plan. This Agreement may be executed in one or more counterparts all of which together shall constitute but one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment to you of your receipt or exercise of this Option or upon your sale or other disposition of the Optioned Shares. You should rely on your own tax advisors for such advice.

9. Certain Remedies.

(a) If at any time within two years after termination of employment or association with the Company and its Affiliates any of the following occur:

(i) you unreasonably refuse to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;

(ii) you accept employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or you otherwise engage in competition with the Company or its Affiliates;

(iii) you act against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting your new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;

(iv) you fail to protect and safeguard while in your possession or control, or surrender to the Company upon termination of your employment or association with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by you;

(v) you solicit or encourage any person or enterprise with which you have had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) you breach any confidentiality obligations you have to the Company or an Affiliate, you fail to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, you use confidential information of the Company or its Affiliates for your own benefit or gain, or you disclose or otherwise misuse confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

- (1) this Option shall terminate and be cancelled effective the date on which you enter into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Option or the Plan;
- (2) any stock acquired and held by you pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$12.37 per share; and
- (3) any gain realized by you from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by you to the Company;

(b) The term “Applicable Period” shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to your termination of employment or association with the Company or any Affiliate and ending two year from your termination of employment or association with the Company or any Affiliate.

(c) The term “Competitive Enterprise” shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company’s products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended from time to time upon notice to you. At any time you may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from you about the enterprise, and the determination will be valid for a period of 90 days from the date of determination.

10. Right of Set Off. By executing this Agreement, you consent to a deduction from any amounts the Company or any Affiliate owes you from time to time, to the extent of the amounts you owe the Company under Paragraph 9 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to you to the extent that exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount you owe it, calculated as set forth above, you agree to pay immediately the unpaid balance to the Company upon the Company’s demand.

11. Nature of Remedies.

(a) The remedies set forth in Sections 9 and 10 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 9(a). The Company shall also be entitled to issue stop transfer instructions to the Company’s stock transfer agent in the event the Company believes that any event referred to in Section 9(a) has occurred or is reasonably likely to occur.

**TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN**

**Stock Option Agreement
(Bhaskar Rao)**

THIS AGREEMENT dated as of May 11, 2006, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out ("you" or the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan (as the same may be amended from time to time, the "Plan"), the Company grants to you, the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of 25,000 shares (the "Optioned Shares") of the common stock, par value \$.01 per share, of the Company (the "Stock"), at a price of \$14.77 per share. The Grant Date of this Option is May 11, 2006.
Character of Option. This Option is not to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on May 11, 2016. However, if your employment or other association with the Company and its Affiliates ends before that date (including because your employer ceased to be an Affiliate), this Option shall expire at 5:00 p.m. on May 11, 2016 if earlier, the date specified in whichever of the following applies:

(a) If the termination of your employment or other association is on account of your death or disability, the first anniversary of the date your employment ends.

(b) If the termination of your employment or other association is due to any other reason, three (3) months after your employment or other association ends.

4. Exercise of Option.

(a) Until this Option expires, you may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after your employment or other association with the Company and its Affiliates ends, including because your employer ceased to be an Affiliate, you may exercise it only to the extent it was exercisable immediately prior to the end of your employment or other association. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. You may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided you have owned such shares of Stock for at least six months.

Number of Shares in Each Installment	Initial Exercise Date for Shares in Installment
6,250	May 11, 2007
6,250	May 11, 2008
6,250	May 11, 2009
6,250	May 11, 2010

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, you may not transfer this Option except by will or the laws of descent and distribution, and, during your lifetime, only you may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 (Settlement of Awards).

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof, and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee. Capitalized terms used but not defined herein shall have the meaning assigned under the Plan. This Agreement may be executed in one or more counterparts all of which together shall constitute one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment to you of your receipt or exercise of this Option or upon your sale or other disposition of the Optioned Shares. You should rely on your own tax advisors for such advice.

9. Certain Remedies.

(a) If at any time within two years after termination of your employment or association with the Company and its Affiliates any of the following occur:

(i) you unreasonably refuse to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;

(ii) you accept employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or you otherwise engage in competition with the Company or its Affiliates;

(iii) you act against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting your new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;

(iv) you fail to protect and safeguard while in your possession or control, or surrender to the Company upon termination of your employment or association with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by you;

(v) you solicit or encourage any person or enterprise with which you have had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) you breach any confidentiality obligations you have to the Company or an Affiliate, you fail to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, you use confidential information of the Company or its Affiliates for your own benefit or gain, or you disclose or otherwise misuse confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

(1) this Option shall terminate and be cancelled effective as of the date on which you entered into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Agreement or the Plan;

(2) any stock acquired and held by you pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$14.77 per share; and

(3) any gain realized by you from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by you to the Company;

(b) The term “Applicable Period” shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to your termination of employment or association with the Company or any Affiliate and ending two years from your termination of employment or association with the Company or any Affiliate.

(c) The term “Competitive Enterprise” shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company’s products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended from time to time upon notice to you. At any time you may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from you about the enterprise, and the determination will be valid for a period of 90 days from the date of determination.

10. Right of Set Off. By executing this Agreement, you consent to a deduction from any amounts the Company or any Affiliate owes you from time to time, to the extent of the amounts you owe the Company under Paragraph 9 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to you to the extent that the exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount you owe the Company, calculated as set forth above, you agree to pay immediately the unpaid balance to the Company upon the Company’s demand.

11. Nature of Remedies.

(a) The remedies set forth in Sections 9 and 10 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 9(a). The Company shall also be entitled to issue stop transfer instructions to the Company’s stock transfer agent in the event the Company believes that any event referred to in Section 9(a) has occurred or is reasonably likely to occur.

**TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN**

Stock Option Agreement

(David Montgomery)

This Agreement dated as of June 28, 2006, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan (as the same may be amended from time to time, the "Plan"), the Company grants to the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of three hundred fifty thousand (350,000) shares (the "Optioned Shares") of the Company's common stock, par value \$0.01 per share, (the "Stock"), at a price of \$13.47 per share. The Grant Date of this Option is June 28, 2006.

2. Character of Option. This Option is not to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on June 28, 2016. However, if the Optionee's employment with the Company and its Affiliates ends before that date (including because the Optionee's employer ceases to be an Affiliate), this Option shall expire on the earlier date specified in whichever of the following applies:

- (a) If the termination of the Optionee's employment is on account of the Optionee's death or disability, the first anniversary of the date the Optionee's employment ends; or
- (b) If the termination of the Optionee's employment is due to any other reason, three (3) months after the Optionee's employment ends.

4. Exercise of Option.

(a) Until this Option expires, the Optionee may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after the Optionee's employment with the Company and its Affiliates ends, including because the Optionee's employer ceases to be an Affiliate, the Optionee may exercise it only to the extent it was exercisable immediately prior to the end of the Optionee's employment. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. The Optionee may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided the Optionee has owned such shares of Stock for at least six months.

Number of Shares in Each Installment	Percentage of Optioned Shares	Initial Exercise Date for Shares in Installment
87,500	25%	February 24, 2008
21,875	6.25%	May 24, 2008
21,875	6.25%	August 24, 2008
21,875	6.25%	November 24, 2008
21,875	6.25%	February 24, 2009

21,875	6.25%	May 24, 2009
21,875	6.25%	August 24, 2009
21,875	6.25%	November 24, 2009
21,875	6.25%	February 24, 2010
21,875	6.25%	May 24, 2010
21,875	6.25%	August 24, 2010
21,875	6.25%	November 24, 2010
21,875	6.25%	February 24, 2011

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, this Option may not be transferred except by will or the laws of descent and distribution, and, during the Optionee's lifetime, only the Optionee may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 of the Plan ("Settlement of Awards"). Capitalized terms used but not defined herein shall have the meaning assigned under the Plan.

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof, and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee. This Agreement may be executed in one or more counterparts all of which together shall constitute one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment of this Option or the exercise of this Option or upon the Optionee's sale or other disposition of the Optioned Shares. The Optionee should rely on his own tax advisors for such advice.

9. Certain Remedies.

(a) If at any time within two years after termination of the Optionee's employment with the Company and its Affiliates any of the following occur:

- (i) the Optionee unreasonably refuses to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;
- (ii) the Optionee accepts employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or the Optionee otherwise engages in competition with the Company or its Affiliates;
- (iii) the Optionee acts against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting his new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;
- (iv) the Optionee fails to protect and safeguard while in the Optionee's possession or control, or surrender to the Company upon termination of the Optionee's employment with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or

otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by the Optionee;

(v) the Optionee solicits or encourages any person or enterprise with which the Optionee has had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) the Optionee breaches any confidentiality obligations the Optionee has to the Company or an Affiliate, the Optionee fails to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, the Optionee uses confidential information of the Company or its Affiliates for the Optionee's own benefit or gain, or the Optionee discloses or otherwise misuses confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

(1) this Option shall terminate and be cancelled effective as of the date on which the Optionee entered into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Agreement or the Plan;

(2) any stock acquired and held by the Optionee pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$13.47 per share; and

(3) any gain realized by the Optionee from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by the Optionee to the Company;

(b) The term "Applicable Period" shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to the Optionee's termination of employment with the Company or any Affiliate and ending two years from the Optionee's termination of employment with the Company or any Affiliate.

(c) The term "Competitive Enterprise" shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company's products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended from time to time upon notice to the Optionee. At any time the Optionee may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from the Optionee about the enterprise, and the determination will be valid for a period of ninety (90) days from the date of determination.

10. Right of Set Off. By executing this Agreement, the Optionee consents to a deduction from any amounts the Company or any Affiliate owes the Optionee from time to time, to the extent of the amounts the Optionee owes the Company under Paragraph 9 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to the Optionee to the extent that the exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount the Optionee owes the Company, calculated as set forth above, the Optionee agrees to pay immediately the unpaid balance to the Company upon the Company's demand.

11. Nature of Remedies.

(a) The remedies set forth in Sections 9 and 10 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 9(a). The Company shall also be entitled to issue stop transfer instructions to the Company's stock transfer agent in the event the Company believes that any event referred to in Section 9(a) has occurred or is reasonably likely to occur.

TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN

Stock Option Agreement

(Dale E. Williams)

This Agreement dated as of June 28, 2006, between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan (as the same may be amended from time to time, the "Plan"), the Company grants to the Optionee, an option (the "Option") to purchase from the Company all or any part of a total of two hundred fifty thousand (250,000) shares (the "Optioned Shares") of the Company's common stock, par value \$0.01 per share, (the "Stock"), at a price of \$13.47 per share. The Grant Date of this Option is June 28, 2006.

2. Character of Option. This Option is not to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on June 28, 2016. However, if the Optionee's employment with the Company and its Affiliates ends before that date (including because the Optionee's employer ceases to be an Affiliate), this Option shall expire on the earlier date specified in whichever of the following applies:

(a) If the termination of the Optionee's employment is on account of the Optionee's death or disability, the first anniversary of the date the Optionee's employment ends; or

(b) If the termination of the Optionee's employment is due to any other reason, three (3) months after the Optionee's employment ends.

4. Exercise of Option.

(a) Until this Option expires, the Optionee may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after the Optionee's employment with the Company and its Affiliates ends, including because the Optionee's employer ceases to be an Affiliate, the Optionee may exercise it only to the extent it was exercisable immediately prior to the end of the Optionee's employment. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. The Optionee may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided the Optionee has owned such shares of Stock for at least six months.

<u>Number of Shares in Each Installment</u>	<u>Percentage of Optioned Shares</u>	<u>Initial Exercise Date for Shares in Installment</u>
62,500	25%	July 7, 2008
15,625	6.25%	October 7, 2008
15,625	6.25%	January 7, 2009
15,625	6.25%	April 7, 2009
15,625	6.25%	July 7, 2009
15,625	6.25%	October 7, 2009

15,625	6.25%	January 7, 2010
15,625	6.25%	April 7, 2010
15,625	6.25%	July 7, 2010
15,625	6.25%	October 7, 2010
15,625	6.25%	January 7, 2011
15,625	6.25%	April 7, 2011
15,625	6.25%	July 7, 2011

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, this Option may not be transferred except by will or the laws of descent and distribution, and, during the Optionee's lifetime, only the Optionee may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 of the Plan ("Settlement of Awards"). Capitalized terms used but not defined herein shall have the meaning assigned under the Plan.

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof, and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee. This Agreement may be executed in one or more counterparts all of which together shall constitute one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment of this Option or the exercise of this Option or upon the Optionee's sale or other disposition of the Optioned Shares. The Optionee should rely on his own tax advisors for such advice.

9. Certain Remedies.

(a) If at any time within two years after termination of the Optionee's employment with the Company and its Affiliates any of the following occur:

(i) the Optionee unreasonably refuses to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;

(ii) the Optionee accepts employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or the Optionee otherwise engages in competition with the Company or its Affiliates;

(iii) the Optionee acts against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting his new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;

(iv) the Optionee fails to protect and safeguard while in the Optionee's possession or control, or surrender to the Company upon termination of the Optionee's employment with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by the Optionee;

(v) the Optionee solicits or encourages any person or enterprise with which the Optionee has had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) the Optionee breaches any confidentiality obligations the Optionee has to the Company or an Affiliate, the Optionee fails to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, the Optionee uses confidential information of the Company or its Affiliates for the Optionee's own benefit or gain, or the Optionee discloses or otherwise misuses confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

(1) this Option shall terminate and be cancelled effective as of the date on which the Optionee entered into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Agreement or the Plan;

(2) any stock acquired and held by the Optionee pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$13.47 per share; and

(3) any gain realized by the Optionee from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by the Optionee to the Company;

(b) The term "Applicable Period" shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to the Optionee's termination of employment with the Company or any Affiliate and ending two years from the Optionee's termination of employment with the Company or any Affiliate.

(c) The term "Competitive Enterprise" shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company's products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended from time to time upon notice to the Optionee. At any time the Optionee may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from the Optionee about the enterprise, and the determination will be valid for a period of ninety (90) days from the date of determination.

10. Right of Set Off. By executing this Agreement, the Optionee consents to a deduction from any amounts the Company or any Affiliate owes the Optionee from time to time, to the extent of the amounts the Optionee owes the Company under Paragraph 9 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to the Optionee to the extent that the exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount the Optionee owes the Company, calculated as set forth above, the Optionee agrees to pay immediately the unpaid balance to the Company upon the Company's demand.

11. Nature of Remedies.

(a) The remedies set forth in Sections 9 and 10 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 9(a). The Company shall also be entitled to issue stop transfer instructions to the Company's stock transfer agent in the event the Company believes that any event referred to in Section 9(a) has occurred or is reasonably likely to occur.

**TEMPUR-PEDIC INTERNATIONAL INC.
2003 EQUITY INCENTIVE PLAN**

**Stock Option Agreement
([NAME])**

This Agreement dated as of [Date], between Tempur-Pedic International Inc., a corporation organized under the laws of the State of Delaware (the "Company"), and the individual identified below, residing at the address there set out (the "Optionee").

1. Grant of Option. Pursuant and subject to the Company's 2003 Equity Incentive Plan (as the same may be amended from time to time, the "Plan"), the Company grants to the Optionee an option (the "Option") to purchase from the Company all or any part of a total of [number] shares (the "Optioned Shares") of the Company's common stock, par value \$0.01 per share (the "Stock"), at a price of \$[] per share. The Grant Date of this Option is [].

2. Character of Option. This Option is [not] to be treated as an "incentive stock option" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

3. Duration of Option. Subject to the following sentence, this Option shall expire at 5:00 p.m. on [ten years from Grant Date]. However, if the Optionee's employment with the Company and its Affiliates ends before that date (including because the Optionee's employer ceases to be an Affiliate), this Option shall expire on the earlier date specified in whichever of the following applies:

- (a) If the termination of the Optionee's employment is on account of the optionee's death or disability, the first anniversary of the date the Optionee's employment ends; or
- (b) If the termination of the Optionee's employment is due to any other reason, three (3) months after the Optionee's employment ends.

4. Exercise of Option.

(a) Until this Option expires, the Optionee may exercise it as to the number of Optioned Shares identified in the table below, in full or in part, at any time on or after the applicable exercise date or dates identified in the table. However, during any period that this Option remains outstanding after the Optionee's employment with the Company and its Affiliates ends, including because the Optionee's employer ceases to be an Affiliate, the Optionee may exercise it only to the extent it was exercisable immediately prior to the end of the Optionee's employment. The procedure for exercising this Option is described in Section 7.1(e) of the Plan. The Optionee may pay the exercise price due on exercise by delivering other shares of Stock of equivalent Market Value provided the Optionee has owned such shares of Stock for at least six months.

Number of Shares in Each Installment	Percentage of Optioned Shares	Initial Exercise Date for Shares in Installment
---	----------------------------------	--

5. Transfer of Option. Except as provided in Section 6.4 of the Plan, this Option may not be transferred except by will or the laws of descent and distribution, and during the Optionee's lifetime, only the Optionee may exercise this Option.

6. Incorporation of Plan Terms. This Option is granted subject to all of the applicable terms and provisions of the Plan, including but not limited to the limitations on the Company's obligation to deliver Optioned Shares upon exercise set forth in Section 10 of the Plan, "Settlement of Awards". Capitalized terms used but not defined herein shall have the meaning assigned under the Plan.

7. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof, and shall be binding upon and inure to the benefit of any successor or assign of the Company and any executor, administrator, trustee, guardian, or other legal representative of the Optionee. This Agreement may be executed in one or more counterparts all of which together shall constitute one instrument.

8. Tax Consequences. The Company makes no representation or warranty as to the tax treatment of this Option, including upon the exercise of this Option or upon the Optionee's sale or other disposition of the Optioned Shares. The Optionee should rely on his/her own tax advisors for such advice.

9. Certain Remedies.

(a) If at any time within two years after termination of the Optionee's employment with the Company and its Affiliates any of the following occur:

(i) the Optionee unreasonably refuses to comply with lawful requests for cooperation made by the Company, its board of directors, or its Affiliates;

(ii) the Optionee accepts employment or a consulting or advisory engagement with any Competitive Enterprise of the Company or its Affiliates or the Optionee otherwise engages in competition with the Company or its Affiliates;

(iii) the Optionee acts against the interests of the Company and its Affiliates, including recruiting or employing, or encouraging or assisting the Optionee's new employer to recruit or employ an employee of the Company or any Affiliate without the Company's written consent;

(iv) the Optionee fails to protect and safeguard while in his/her possession or control, or surrender to the Company upon termination of the Optionee's employment with the Company or any Affiliate or such earlier time or times as the Company or its board of directors or any Affiliate may specify, all documents, records, tapes, disks and other media of every kind and description relating to the business, present or otherwise, of the Company and its Affiliates and any copies, in whole or in part thereof, whether or not prepared by the Optionee;

(v) the Optionee solicits or encourages any person or enterprise with which the Optionee has had business-related contact, who has been a customer of the Company or any of its Affiliates, to terminate its relationship with any of them; or

(vi) the Optionee breaches any confidentiality obligations the Optionee has to the Company or an Affiliate, the Optionee fails to comply with the policies and procedures of the Company or its Affiliates for protecting confidential information, the Optionee uses confidential information of the Company or its Affiliates for his/her own benefit or gain, or your disclose or other misuse confidential information or materials of the Company or its Affiliates (except as required by applicable law); then

(1) this Option shall terminate and be cancelled effective as of the date on which the Optionee entered into such activity, unless terminated or cancelled sooner by operation of another term or condition of this Agreement or the Plan;

(2) any stock acquired and held by the Optionee pursuant to the exercise of this Option during the Applicable Period (as defined below) may be repurchased by the Company at a purchase price of \$[] per share; and

(3) any gain realized by the Optionee from the sale of stock acquired through the exercise of this Option during the Applicable Period shall be paid by the Optionee to the Company;

(b) The term “Applicable Period” shall mean the period commencing on the later of the date of this Agreement or the date which is one year prior to the Optionee’s termination of employment with the Company or any Affiliate and ending two years from the Optionee’s termination of employment with the Company or any Affiliate.

(c) The term “Competitive Enterprise” shall mean a business enterprise that engages in, or owns or controls a significant interest in, any entity that engages in, the manufacture, sale or distribution of mattresses or pillows or other bedding products or other products competitive with the Company’s products. Competitive Enterprise shall include, but not be limited to, the entities set forth on Appendix A hereto, which may be amended by the Company from time to time upon notice to the Optionee. At any time the Optionee may request in writing that the Company make a determination whether a particular enterprise is a Competitive Enterprise. Such determination will be made within 14 days after the receipt of sufficient information from the Optionee about the enterprise, and the determination will be valid for a period of 90 days from the date of determination.

10. Right of Set Off. By executing this Agreement, the Optionee consents to a deduction from any amounts the Company or any Affiliate owes the Optionee from time to time, to the extent of the amounts the Optionee owes the Company under Paragraph 9 above, provided that this set-off right may not be applied against wages, salary or other amounts payable to the Optionee to the extent that the exercise of such set-off right would violate any applicable law. If the Company does not recover by means of set-off the full amount the Optionee owes the Company, calculated as set forth above, the Optionee agrees to pay immediately the unpaid balance to the Company upon the Company’s demand.

11. Nature of Remedies.

(a) The remedies set forth in Sections 9 and 10 above are in addition to any remedies available to the Company and its Affiliates in any non-competition, employment, confidentiality or other agreement, and all such rights are cumulative. The exercise of any rights hereunder or under any such other agreement shall not constitute an election of remedies.

(b) The Company shall be entitled to place a legend on any certificate evidencing any stock acquired upon exercise of this Option referring to the repurchase right set forth in Section 9(a). The Company shall also be entitled to issue stop transfer instructions to the Company’s stock transfer agent in the event the Company believes that any event referred to in Section 9(a) has occurred or is reasonably likely to occur.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

TEMPUR-PEDIC INTERNATIONAL INC.

By: _____
Title: _____

Signature of Optionee

Name of Optionee

Optionee's Address:

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, H. Tomas Bryant, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tempur-Pedic International Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2006

/s/ H. THOMAS BRYANT

H. Thomas Bryant
Chief Executive Officer and President

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Dale E. Williams, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Tempur-Pedic International Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2006

/s/ DALE E. WILLIAMS

Dale E. Williams
Senior Vice President, Chief Financial Officer, And Secretary

